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used  mouse  models  of  diet  induced  hyperinsulinemia  by  providing  a  high 








In  Chapter  III  we  show  that  the  effects  of  diet  and  metformin  on  tumor 
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In  accordance with  the  guidelines  published  by McGill  University,  this  thesis  is  a 




attenuates  the  stimulatory  effect  of  a  high  energy  diet  in  vivo  LLC1  carcinoma 
growth. Endocrine Related Cancer. 2008; 15(3):833‐9. 
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increased  cancer  risk  and  poorer  prognosis  for  cancer  [4,  5].    It  has  been 
suggested  that  15‐20%  of  cancer  deaths  in  the  United  States  can  be 
attributed  to  the  patient  being  overweight  or  obese  [4].    Many  molecular 
mechanisms have been proposed to explain the link between these diseases.  
The  influence  of  energy  intake  on  tumor  growth  has  been  studied 
experimentally  since  the  1940’s  [6,  7]  and  the  inhibitory  effect  of  caloric 
restriction  on  tumor  burden  is  well  documented  [8,  9].    The  epidemic  of 
obesity and the well‐documented adverse effect of obesity and excess energy 
intake  on  cancer  burden  has  led  to  a  surge  in  reports  of  experiments 
searching  to  better  define  the  mechanistic  link  between  metabolism  and 
cancer  [10‐12].    Presently,  most  evidence  supports  mechanisms  linking 
obesity and cancer via the endocrine derangements caused by obesity[13‐15] 
and,  as  discussed  below,  insulin  and  IGF‐I  signaling  are  currently  two 




The  insulin  IGF  family consists  of at  least  three  ligands:  insulin,  insulin‐like 
growth  factor  I and  II  (IGF‐I and  IGF‐II), and their receptors.  Insulin  is best 
known  for  its  role  in  glucose  and  energy  homeostasis  while  IGFs  play  a 
critical role in normal growth and development in humans and animals.  IGF‐
I levels are known to peak at puberty, but significant levels of both IGF‐I and 
IGF‐II  are  detectable  throughout  adulthood  [16].  Three  of  the  relevant 
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Insulin  is  a peptide hormone  secreted by  the pancreas  and  regulates many 
pathways including protein synthesis, lipid synthesis and storage, glycolysis, 
glucose  uptake  and  storage,  the  inhibition  of  ketogenesis  and 
gluconeogenesis [26].  The immature form of insulin, pro‐insulin, is secreted 




hold  up  to  200  000  molecules  of  insulin  [28].    Once  secreted,  pro‐insulin 
must be cleaved in order to be mature, active insulin.  Maturation is catalyzed 
by three proteases: pro‐hormone convertase 1 and 2 and carboxypeptidase E 
(CPE)  [29].   One of  the peptides  cleaved  from pro‐insulin  is  C‐peptide.      C‐
peptide has a longer half‐life in the blood than insulin and can be used as an 
indicator  of  long‐term  insulin  secretion[30].    While  type  I  diabetes  is  the 
result of ß‐cell failure and insufficient insulin secretion leading to prolonged 
hyperglycemia,  type  II  diabetes  is  characterized  by  hyperinsulinemia  and 
insulin resistance [31]. 
  Insulin  signaling  stimulates  cellular  glucose  uptake,  primarily  in 
muscle and fat  tissues [32].   GLUT4 is  the predominant glucose  transporter 
isoform  expressed  in  these  tissues  and  activation  of  the  insulin  receptor 
leads to translocation of these transporters from intracellular storage sites to 
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Insulin  signaling  also  plays  a  role  in  other  tissues.    For  example, 
insulin  may  also  act  in  the  central  nervous  system  (CNS)  where  it  is 
transported by insulin transporters across the blood‐brain barrier, primarily 
in  the  olfactory  bulb,  hypothalamus,  cerebral  cortex,  cerebellum, 
hippocampus and pituitary intermediate lobe [39‐41].  Through its action in 
the brain,  insulin may be involved in appetite regulation through regulating 




Tyrosine  phosphorylation  of  the  insulin  receptor  ß‐subunit  leads  to  the 
recruitment of “docking proteins”, such as Insulin Receptor Substrates (IRS) 
1‐4  and  several  Shc  proteins.    IRS‐proteins  lack  intrinsic  catalytic  activity; 
however,  they  are  composed  of  multiple  interaction  domains  and 
phosphorylation motifs.    Each  IRS  protein  has  an  amino‐terminal  pleckstin 
homology  (PH)  domain,  a  phospho‐tyrosine  domain  (PTB)  and  a  carboxy‐
terminal domain which encodes numerous tyrosine and serine residues that 
are prone to phosphorylation [43]. 
The  PTB  domains  of  IRS  proteins  interact  with  the  tyrosine‐
phosphorylated  NPXY  sequence  of  the  insulin  receptor  and  IGF‐I  receptor 
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Figure  2:  The  Insulin  Signaling  Pathway.  Autophosphorylation  of  the 
insulin receptor following binding of  insulin  leads to the activation of  IRS‐1 
and downstream signaling components, the uptake of glucose from the blood 
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downstream  of  the  insulin  receptor,  following  alterations  in  protein 
expression  and  activation  of  signaling  molecules.  Insulin  resistance  and 




Several  mechanisms  have  been  proposed  to  explain  the  pathogenesis  of 
insulin  resistance,  including  inflammation  of  adipose  tissue[86],  excessive 
fatty  acid  oxidation[87],  endoplasmic  reticulum  stress[88]  and  negative 
feedback downstream of the insulin receptor [89‐91] (Figure 3). 
It has been observed that skeletal muscle and adipocytes of obese and 
insulin  resistant  individuals  have  reduced  IRS‐1  protein  expression  and 
insulin‐stimulated  tyrosine  phosphorylation,  compared  to  control  subjects 
[92].   Multiple  studies have  suggested  that  serine phosphorylation of  IRS‐1 
leads to insulin resistance by obstructing the interaction between IRS‐1 and 
the  activated  insulin  receptor  [27,  85].    Phosphorylation  of  serine  sites  on 
IRS‐1  proteins  is  tightly  regulated  and  complex,  exhibiting  positive  or 
negative  effects  on  insulin  signaling  depending  on  the  tissue  and  the 
phosphorylation  of  related  protein  kinases  [93,  94].  IRS‐1  contains  more 
than 20 potential serine phosphorylation sites in amino acid sequence motifs 
that  can  be  recognized  by  protein  kinase  A,  AKT, mTOR,  AMPK  and  S6K‐1 
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to  be  effective  when  used  as  monotherapy  [136‐138].  The  drug  was 
synthesized  in  1922  [139]and  its  glucose  lowering  action  in  dogs was  first 
described in 1929.  Metformin was used in clinical trials commencingin 1957 
and is now the most prescribed drug for the treatment of type II diabetes in 





The  active  ingredient  in  these  plants  was  determined  to  be  isoamylene 
guanidine and biguanides, such as metformin and phenformin, were derived 
from this natural medicinal compound [140].     Metformin, a small molecule, 
is  taken  up  by  cells  via  the  OCT  1  transporter  [144,  145].    It  is  excreted 
quickly via  the renal  system, unmetabolized, with 90% clearance within 24 
hours  [136].    The  drug  is  not  protein  bound  and  has  wide  volume 
distribution,  with  maximal  accumulation  in  the  wall  of  the  small  intestine 
following  oral  ingestion  [146].  The  blood  glucose‐lowering  effects  of 
metformin  are  primarily  a  consequence  of  reduced  hepatic  glucose  output 
[141].  At  the  cellular  level,  metformin  acts  in  the  mitochondria  as  a  mild 
inhibitor  of  complex  I  of  the  respiratory  chain  [142,  143].    This  mild 
inhibition  of  oxidative  phosphorylation,  the  source  of  the  majority  of  ATP 
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leads  to  decreased  gluconeogenesis  through  its  indirect  activation  of 
AMPK[141].   This pivotal  study showed  that  injecting mice with metformin 
led to phosphorylation of AMPK in hepatocytes in mice that expressed LKB1 
but not in mice with a liver specific deletion of LKB1.  Using these mice, it was 
reported  that metformin  reduced  glucose  output  by  50%  in wildtype mice 
but did not change glucose output in LKB1 null mice. This decrease in glucose 
output  by  the  liver,as  a  result  of metformin  exposure,  can  indirectly  lower 







LKB1,  also  known  as  STK11,  is  a  serine‐threonine  kinase  and  a  tumor 
suppressor.    LKB1  was  first  identified  as  the  tumor  suppressor  gene  on 
human  chromosome  19p13  and  inactivating mutations  are  responsible  for 





lung  [151],  breast,  ovarian  and  cervical  [152,  153].    LKB1  exists  as  a 
heterotrimeric complex of LKB1 and its regulatory subunits STRAD (STE20‐
related adaptor) and MO25 (also known as CAB39) (reviewed in [153, 154]).  
LKB1  phosphorylates  and  activates  14  downstream  kinases,  most  notably 
AMPKα1 and AMPKα2 which  interact with AMPKγ under conditions of  low 
ATP  [155,  156].  Through  its  action  as  a  master  kinase,  LKB1  and  its 
downstream  target  kinases  play  a  role  in  cell  growth  and  metabolism 
through the activation of widely expressed transcriptional co‐activators.  The 





In  mammals,  AMPK  has  a  conserved  evolutionary  role  as  a  regulator  of 
energy homeostasis  at  the  cellular  level  and  is  involved  in many metabolic 
processes,  including  gluconeogenesis,  fatty  acid  oxidation  and  glucose 
transport  [38,  156].    AMPK,  a  sensor  of  intracellular  energy  status,  is 








two  mechanisms:  1)  allosteric  activation  of  phosphorylated  AMPK  and  2) 




concentrations  [161,  162].    When  activated,  AMPK  slowscell  proliferation 
primarily its effects on the mTOR pathway.  When ATP levels are low, AMPK 
directly  phosphorylates  TSC2  on  conserved  serine  site  and  suppresses 
mTORC1  activity.    AMPK  up‐regulates  energy  generating  processes  and 
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death  from  cancer  suggest  metformin  may  also  be  acting  to  prevent  new 
cancers  and/or  slow  the  growth  of  existing  cancer  such  that  they  remain 
subclinical.  Recent experimental data [175, 176] showed that metformin can 
reduce tumor burden of a carcinogen‐induced model of lung cancer and that 
metformin  slows  epithelial  cell  turnover  in  the  small  intestine  of  healthy 
volunteers.   
In my work,  I  used animals with diet  induced hyperinsulinemia and 
obesity to examine the activity and mechanisms relevant to metformin action 
in  vivo.  In  particular,  we  were  interested  in  the  ‘direct’  AMPK  mediated 



















? n (%)? Unadjusted Adjusted*
Incidence?of?bowel?cancer? ?
Comparators ? 76?(1.9) 1.00 1.00?
Users    ? 40?(1.0) 0.41?(0.28–0.61) 0.60?(0.38–
0.94)?
Incidence?of?lung?cancer? ?
Comparators ? 58?(1.4) 1.00 1.00?





Comparators ? 41?(2.2) 1.00 1.00?
Users    ? 24?(1.3) 0.44?(0.26–0.73) 0.60?(0.32–
1.10)?
Overall?mortality? ?
Comparators ? 1,422?(34.8) 1.00 1.00?
Users    ? 609?(14.9) 0.32?(0.29–0.35) 0.42?(0.38–
0.47)?
Mortality?from?cancer? ?
Comparators ? 248?(6.1) 1.00 1.00?
Users    ? 123?(3.0) 0.48?(0.39–0.60) 0.63?(0.49–
0.81)?
Incidence?of?cancer? <2?years?follow?up* 2–4?years?follow?up*? >4?years?
follow?up*?
Maximum?prescribed?dose?
during    ?follow?up?(n)??
?
Low?(1,017)? 3.15?(1.92–5.18) 0.99?(0.44–2.25) 0.16?(0.06–
0.44)?
Medium?(2,090)? 1.94?(1.20–3.13) 0.51?(0.31–0.82) 0.40?(0.27–
0.60)?
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As described  in Chapter  I,  retrospective epidemiologic data has  shown  that 
diabetic  patients  taking metformin  for  their  diabetes  have  reduced  risk  of 
developing cancer compared to diabetic patients taking other therapies [166, 
167].  This paper was followed up by Zakikhani et al [169] who showed that 
metformin  can  slow  proliferation  of  MCF‐7  breast  cancer  cells  in  vitro 
through the LKB1‐dependent activation of AMPK; however, it was unclear if 
this mechanism is relevant to tumor growth in vivo.  In Chapter II, we sought 


















We  investigated  the  effects  of  metformin  on  the  growth  of  Lewis  lung 
carcinoma  in  C57BL/6  mice  provided  with  either  a  control  diet  or  a  high 
energy diet, previously reported to lead to weight gain and systemic insulin 
resistance with hyperinsulinemia. 48 male mice were randomized  into  four 
groups:  control  diet,  control  diet  +  metformin,  high  energy  diet  and  high 
energy  +  metformin.    Following  eight  weeks  on  the  experimental  diets, 
selected  groups  received  metformin  in  the  drinking  water.  Three  weeks 
following the start of metformin treatment, mice were injected with 0.5 x 106 
LLC1 cells and tumor growth was measured for 17 days. By day 17, tumors of 
mice  on  the  high  energy  diet  were  nearly  twice  the  volume  compared  to 
tumors of mice on the control diet. This effect of diet on tumor growth was 
significantly  attenuated  by metformin,  but metformin  had  no  effect  on  the 
tumor  growth  of  the  mice  on  the  control  diet.    Metformin  attenuated  the 
increased  insulin  receptor  activation  observed  in  tumor  tissue  taken  from 
mice  consuming  the  high  energy  diet  and  also  led  to  increased 
phosphorylation of AMPK, two actions which would be expected to decrease 
neoplastic  proliferation.    These  experimental  results  are  consistent  with 
prior  hypothesis‐generating  epidemiologic  studies  that  suggest  metformin 
may reduce cancer risk and improve cancer prognosis.  Finally, these results 
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Figure?3:? Impact?of?diet? and?metformin?on? tumor? growth? in? vivo.?????
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other  AMPK  activators  [178]  in  cancer  treatment  and  prevention.    We 
confirmed  the  results  of  a  prior  report  [10]  showing  a  high  energy  diet  is 
associated with more aggressive tumor behavior in the LLC1 model.   We also 
observed  that  metformin  almost  completely  attenuated  the  effect  of  high 
energy diet  on  tumor  growth, while  having no  significant  impact  on  tumor 
growth of animals on the control diet.  
Prior  experiments  provide  evidence  that  AMPK  activation  by 
metformin  leads  to  growth  inhibition  of  cancer  cells  in  vitro[169].      We 
studied  the  in vivo  effects  of metformin  on  tumor  growth  and  employed  a 
model  that allowed us  to make observations under standard control  in vivo 
conditions  and  also  under  conditions  of  dietary‐induced  hyperinsulinemia 
and systemic insulin resistance.    In addition, our model allowed us to study 
tumor  growth  in  the  context  of  the metabolic  characteristics  of metformin 
treated  patients  with  type  II  diabetes,  where  there  is  early  epidemiologic 
evidence of possible anti‐neoplastic activity of the drug [166, 168]. 
The finding that metformin attenuates the stimulatory effect of a high 
energy  diet  on  tumor  growth  in  this  model,  but  has  no  effect  on  baseline 
tumor  growth  is  intriguing.    The  signaling  data  provide  evidence  that 
metformin, at the dose and route we employed, activates AMPK in neoplastic 
tissue  in  animals  on  both  a  control  and  a  high  energy  diet;  however, 
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The  molecular  mechanisms  responsible  for the  association  of  obesity  with 
adverse colon cancer outcomes are poorly understood. We  investigated  the 
effects  of  a  high  energy  diet  on  growth  of  an  in vivo  colon  cancer  model. 
Following the injection of MC38 colon carcinoma cells, tumors from mice on 
the  high  energy  diet  were  approximately  twice  the  volume  compared  to 
those  of mice  on  the  control  diet.  These  findings were  correlated with  the 
observation  that  the  high  energy  diet  led  to  elevated  insulin  levels, 
phosphorylated AKT and  increased expression of  fatty acid synthase by the 
tumor cells.  
Metformin,  an anti‐diabetic drug,  leads  to  activation of AMPK and  is 
currently  under  investigation  for  its  anti‐neoplastic  activity.  We  observed 
that metformin blocked the effect of  the high energy diet on tumor growth, 
reduced  blood  insulin  concentration  and  attenuated  the  effect  of  diet  on 
phosphorylation of AKT and expression of fatty acid synthase. Furthermore, 




behavior  associated  with  a  high  energy  diet  has  similar  effects  on  this 
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into  4  groups:  Control Diet  ± metformin  or High Energy Diet  ± metformin. 
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Figure? 1C:? ? IGF?I? concentration? is? influenced? by? diet? but? not? by?
metformin.?????? ????????????????????????????????????????????????????????????
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Figure?1D:? High?Energy?Diet? consumption? is?associated?with?greater?
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There  are  limited  prior  experimental  data  concerning  the  relationship  of 
excess  energy  intake  to  colorectal  cancer  biology,  despite  the  fact  that 
population  studies  suggest  that  diet  has  an  important  influence  on  tumor 
behavior [10].  We observed in a murine model that increased caloric and fat 
intake leads to an increase in insulin levels, an increase in AKT activation in 




the  biomarker  changes  observed  in mice  in  the  high  energy  dietary  group. 
Our  findings  concerning  the  effects  of  metformin  on  signaling  pathways 
suggest that in our model, the drug may act on neoplastic cells by both direct, 
AMPK  mediated,  and  indirect  insulin  mediated  mechanisms.  As  expected, 
metformin reduced the high levels of insulin seen in mice consuming a high 
energy diet. This action of metformin has been shown to be a consequence of 
activation  of  the  LKB1‐AMPK  pathway  in  liver,  which  results  in  decreased 
gluconeogenesis,  decreased  hepatic  glucose  output,  reduced  circulating 
glucose,  and  a  secondary  decline  in  insulin  [148].    This  correlated  with 
reduced AKT  activation  in  the  colon  cancers  in  our model,  an  effect which 
would be expected to reduce proliferation.  
Separately,  we  detected  increased  activation  of  AMPK  in  neoplastic 
tissue,  which  is  the  expected  consequence  of metformin  acting  directly  on 
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LKB1  knockdown  leads  to  resistance  to  the  direct  in  vitro  AMPK 
dependent growth inhibitory effects of metformin  
Figure  1A  shows  that  transfection  of  MC38  colon  carcinoma  or  lewis  lung 
carcinoma  (LLC1)  cells  with  shRNA  against  LKB1  reduced  expression  of 
LKB1.  For  LKB1  shRNA,  two  shRNAs were used  and  the  results  shown  are 
from one selected colony from each shRNA (‘F’ or ‘G’).  The phosphorylation 
and activation of AMPK requires the presence of functional LKB1 [156] and 
previous  reports  [169,  170]  have  shown  that,  when  LKB1  is  functional, 
exposure  of  neoplastic  cells  to  5mM  metformin  indirectly  leads  to  the 




transfected with  shRNA  against  LKB1  (+F  or  +G) were  resistant  to  growth 
inhibition  by  the  drug.    Figure  1C  shows  that  those  cells  transfected  with 
shRNA  against  LKB1  (referred  to  as  MC38‐LKB1‐  and  LLC1‐LKB1‐)  are 
resistant to AMPK activation and downstream phosphorylation of acetyl CoA 
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Figure? 1B:? Reduced? expression? of? LKB1? renders? cells? insensitive? to?
growth?inhibitory?effects?of?metformin?in?vitro.???????? ???????????? ???????
???????????? ???????????????????????????????????????? ??????????????? ???
??????? ? ????? ???? ????? ?????? ????? ?????????????? ??????? ?????????? ???
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Figure?2A:?High? fat?diet? leads?to?weight?gain.????????????? ???????? ??????
????????? ????????? ????????????????? ?????????????????????? ???????????????? ????


















































Figure? 2C:? Metformin? attenuates? diet? induced? hyperinsulinemia.?
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Tumor? LKB1? expression? is? not? essential? for? in? vivo? anti?neoplastic?
activity?of?metformin?
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tumor  growth  of  MC38‐LKB1‐  cells.  Metformin  abolished  the  stimulatory 
effect  of  the  high  fat  diet  on  tumor  growth  and  unlike  MC38  (Figure  3A), 
metformin significantly attenuated growth of MC38‐LKB1‐ tumors in mice on 
the control diet. High‐fat diet: 1143 ± 127mm3 vs high‐fat diet + metformin: 
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Figure?6:?LKB1?expression? is?required?for?metformin? induced? increase?
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LKB1? expression? influences? cellular? ATP? levels? following?metformin?
exposure.?
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Taken  together,  the  results  presented  in  this  thesis  suggest  that 
metformin  deserves  investigation  in  the  clinic  as  anti‐neoplastic  therapy; 
however, they also suggest that any beneficial effects of the drug may only be 
seen in subsets of patients.  One such subset is predicted to be those patients 
who  have  insulin  sensitive  cancer  and  who  also  have  hyperinsulinemia  at 
baseline; this group may benefit from metformin induced reductions in blood 
insulin  concentration.    Another  group  of  patients  that  may  benefit 
(independent  of  insulin  concentrations)  comprises  those  with  LKB1  null 
tumors  or  LKB1  inactivating  mutations.  For  these  patients,  it  is  the 
metformin‐induced  energy  stress  within  the  tumors  that  could  be 
mechanistically  important.    Unselected  patients,  including  those  who  are 
normo‐insulinemic or have normal LKB1 activity in the tumor, may derive no 
benefit from metformin.  These predictions are in keeping with the view that, 
in  general,  cancer  therapies  do  not  have  equal  effectiveness  in  all  patients 
and that appropriate treatment requires a “personalized medicine” approach.  
It  is  important  to  note  that  these  data  do  not  demonstrate  that 
metformin  can  inhibit  growth  of  well  established  tumors.    In  every  study 
presented here, metformin was either administered before or at  the time of 
tumor  injection  and  the  effects  of  the  drug  on  advanced  cancers  in  mice 
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Endocrine-Related Cancer (2008) 15 849–855Metformin attenuates the stimulatory
effect of a high-energy diet on in vivo
LLC1 carcinoma growthCarolyn Algire1, Mahvash Zakikhani2, Marie-Jose Blouin2,
Jian Hua Shuai2 and Michael Pollak21Division of Experimental Medicine and 2Department of Oncology, Segal Cancer Centre, Jewish General Hospital, McGill University,
3755 Cot Ste. Catherine, Montreal, Quebec, H3T 1E7 Canada
(Correspondence should be addressed to M Pollak; Email: michael.pollak@mcgill.ca)AbstractWe investigated the effects of metformin on the growth of lewis lung LLC1 carcinoma in C57BL/6J
mice provided with either a control diet or a high-energy diet, previously reported to lead to weight
gain and systemic insulin resistance with hyperinsulinemia. Forty-eight male mice were
randomized into four groups: control diet, control dietCmetformin, high-energy diet, or high-
energy dietCmetformin. Following 8 weeks on the experimental diets, selected groups
received metformin in their drinking water. Three weeks following the start of metformin
treatment, mice were injected with 0.5!106 LLC1 cells and tumor growth was measured for
17 days. By day 17, tumors of mice on the high-energy diet were nearly twice the volume of those
of mice on the control diet. This effect of diet on tumor growth was significantly attenuated by
metformin, but metformin had no effect on tumor growth of the mice on the control diet. Metformin
attenuated the increased insulin receptor activation associated with the high-energy diet and also
led to increased phosphorylation of AMP kinase, two actions that would be expected to decrease
neoplastic proliferation. These experimental results are consistent with prior hypothesis-
generating epidemiological studies that suggest that metformin may reduce cancer risk and
improve cancer prognosis. Finally, these results contribute to the rationale for evaluation of the
anti-neoplastic activity of metformin in hyperinsulinemic cancer patients.Endocrine-Related Cancer (2008) 15 849–855Introduction
Population studies provide early circumstantial
evidence that patients with type II diabetes treated
with metformin have reduced cancer incidence
(Evans et al. 2005) and mortality (Bowker et al.
2006, when compared with type II diabetics
receiving alternative therapies). Laboratory studies
have shown that metformin, by lowering the ATP/
AMP ratio, activates the LKB1/AMP kinase
(AMPK) pathway (Hardie 2006) leading to inhi-
bition of gluconeogenesis in hepatocytes (Shaw
et al. 2005). This leads to decreased hepatic glucose
output and a secondary decline in insulin levels,
making the drug useful in the treatment of type II
diabetes. In tumor cells, the gluconeogenic enzymes
found in hepatocytes are not present. However, weEndocrine-Related Cancer (2008) 15 849–855
1351–0088/08/015–849 q 2008 Society for Endocrinology Printed in Greatrecently showed that metformin activates the same
LKB1/AMPK pathway in cancer cells in vitro,
but that in these cells the consequences include
reduced signaling at mTOR and growth inhibition
(Zakikhani et al. 2006).
We wished to extend these in vitro results to an
in vivo model. We chose lewis lung LLC1 carcinoma
model because this experimental tumor has recently
been shown to exhibit particularly aggressive behavior
in mice that are hyperglycemic and obese (Yakar et al.
2006). This model therefore provides an opportunity
to determine whether metformin has anti-neoplastic
activity in vivo, particularly in a metabolic context
similar to that present in the subjects in the
epidemiological studies mentioned above (Evans
et al. 2005, Bowker et al. 2006).Britain
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Randomize into four groups: high-energy diet ± metformin and 
control diet ± metformin
Metformin in drinking water for groups 2 and 4
Experimental diets
Insulin tolerance test






Figure 1 Experimental design. Forty-eight male mice were
randomized into four groups: control diet, control dietC
metformin, high-energy diet, or high-energy dietCmetformin.
Following 8 weeks on the experimental diets, selected groups
received metformin in their drinking water. Three weeks
C Algire et al.: Impact of metformin and diet on tumor growthMaterials and methods
Animals
All experiments performed were approved by the
McGill University Animal Care and Handling Com-
mittee. Forty-eight male C57BL/6J-mice aged 5–6
weeks (Charles River, Saint-Constant, QC, Canada)
were randomized to four groups of 12 mice: control
diet, control dietCmetformin, high-energy diet, and
high-energy dietCmetformin. Food was given
ad libitum. Diets were purchased from Harlan Teklad
(Madison, WI, USA). The high-energy diet (TD
95217) consisted of 18.8% protein, 41.4% carbo-
hydrate, 39.8% fat, and provided 4.3 kcal/g consumed.
The control diet was the standard rodent diet,
Harlan Teklad 2016, which consisted of 16%
protein, 60% carbohydrate, 3.5% fat, and provided
3.3 kcal/g consumed.following the start of metformin treatment, insulin tolerance
tests were performed to determine the metabolic profile of each
dietary group with or without metformin. Mice were then injected
with 0.5!106 LLC1 cells and tumor growth was measured for
17 days.Metformin
Metformin (Spectrum Chemical Corp., New Bruns-
wick, NJ, USA) was added to the drinking water
8 weeks after initiation of the experimental diets.
Metformin was administered at a dose of 50 mg/kg
body weight per day. It was assumed that each mouse
consumed w7 ml water per day. For example, a 30 g
mouse would thus consume 1.5 mg of metformin per
day provided as 7 ml of a 0.214 mg/ml solution.
A pilot study confirmed that addition of metformin
at this concentration did not effect water consumption.
The water and metformin were changed daily and the
dose adjusted for weight gain every 2 weeks.C-peptide
C-peptide was measured following 11 weeks of study.
Blood was taken from fasting mice and was measured
by mouse C-peptide ELISA kit (Gentaur, Aachen,
Germany).Insulin tolerance test
Insulin tolerance tests were performed at noon, 11
weeks after the start of the experimental diets and
3 weeks after mice randomized to metformin had
started to receive the drug (Fig. 1). Mice were injected
i.p. with 0.75 U/kg insulin (Cell Sciences, Canton,
MA, USA). Blood glucose concentration was
measured at the indicated time points using the Ultra
Smart Touch Glucometer and Ultra Smart glucose
strips (Diabetesshop.ca).850Syngeneic tumor model
Mice were injected sc with 0.5!106 lewis lung LLC1
cells (ATCC, Manassas, VA, USA), following 11 weeks
on the experimental diets and 3 weeks after start of the
metformin (Fig. 1). Tumors were palpable 11 days after
injection and were measured daily using electronic
calipers (Lee Valley Tools, Ottawa, ON, Canada).Protein extraction and Western blot analysis
Fat, muscle, liver, and tumor tissue were removed
immediately after the mice were killed. Tissues were
homogenized in 1 ml ice-cold tissue lysis buffer
(20 mM HEPES buffer, 1% Triton X-100, 150 mM
NaCl, 0.02% sodium azide, 60 mM b-glycerophos-
phate, 1 mM sodium vanadate, 1 mM dithiothreitol,
1 Roche complete protease inhibitor tablet, and 5 ml of
5 mM pepstatin A per 50 ml lysis buffer). Lysates were
sonicated and cell debris was removed by centri-
fugation at 18 000 g for 1 h at 4 8C. Following
homogenization, protein content was determined
by protein assay (Bio-Rad). From each tissue
sample, 100 mg of protein were boiled and subjected
to electrophoresis in denaturing 10% SDS-PAGE.
All primary antibodies were purchased from Cell
Signaling Technologies (Danvers, MA, USA), except
the insulin receptor antibody that was purchased
from Chemicon (Temecula, CA, USA), and visualized








































Endocrine-Related Cancer (2008) 15 849–855Statistical analysis
Prior to statistical analysis, data were square-root
transformed to satisfy the assumptions of analysis.
Statistical significance was evaluated using the GLM
Procedure. A one-way ANOVA was used to determine
whether there was significant difference among all
treatment groups. Additionally, Student–Newman–
Keuls test for multiple pairwise comparisons of
means and least-squares means multiple unpairwise
comparisons of means (LSMEANS statement with
Bonferroni correction) were applied. All statistical
analyses were performed using Statistical Analysis
System software, version 9.1.3 (SAS Institute, Cary,




































Control diet High-energy diet High-energy
diet + metformin
Figure 2 (A)Weight gain, by dietary group, over the total 13-week
period. Mice were weighed biweekly. Metformin was given in the
drinking water of the mice daily at a dose of 50 mg/kg body weight
per day. The high-energy diet was associated with increased
weight gain (control diet at 7.2G1.67 g versus high-energy diet at
9.63G2.61 g; *P!0.004). No significant difference in weight gain
was seen between the high-energy diet group and the high-energy
dietCmetformin group. (B) Effect of diet on C-peptide. C-peptide
was measured in fasting mice following 11 weeks on the
experimental diets and 3 weeks on metformin, for select groups.
The high-energy diet was associated with increased C-peptide,
indicating elevated insulin secretion, compared with thosemice on
the control diet (high-energy diet at 1.147G0.134 ng/ml versus
control diet at 0.728G0.028 ng/ml; *P!0.05). Metformin reduced
the elevated C-peptide levels in mice on the high-energy diet;
however, due to small samples size (nZ11), the result did not
reach statistical significance (high-energy diet at 1.147G
0.134 ng/ml versus high-energy dietCmetformin at 0.999G
0.063 ng/ml; PZ0.11). (C) Dietary induced metabolic changes in
mice on a high-energy or control diet with or without metformin.
Sixmiceperdietarygroup received i.p. injectionof0.75U insulinper
kg body weight at noon and blood glucose was analyzed at
indicated time points. Blood glucose concentration: high-energy
diet at tZ45 min: 7.7G0.71 mmol/l versus control diet at
tZ45 min: 3.9G0.19 mmol/l; *P!0.0001. High-energy
dietCmetformin at tZ45 min: 5.47G0.434 mmol/l versus
high-energy diet at tZ45 min: 7.7G0.71 mmol/l; **P!0.05, nZ6.Results
Diet-induced weight and gain and metabolic
changes
Figure 2A shows that mice consuming the high-energy
diet gained more weight during the experiment than
mice on the control diet (9.63G1.67 vs 7.2G1.52 g,
P!0.05). Although metformin occasionally leads to
weight loss in patients due to appetite suppression or
gastrointestinal distress (Kirphichnikov et al. 2002),
we did not observe a significant difference in body
weight between mice randomized to receive metformin
and those that did not receive metformin.
Insulin secretion was estimated by C-peptide ELISA
following 11 weeks on the experimental diets
(Fig. 2B). Consistent with previous studies (Venka-
teswaran et al. 2007), we found the high-energy diet
was sufficient to significantly raise the C-peptide levels
in those mice that received the high-energy diet
compared with those on the control diet (high-energy
diet at 1.147G0.134 ng/ml versus control diet at
0.728G0.028 ng/ml; P!0.05). Interestingly, we
observed that metformin treatment lowered the
C-peptide levels associated with high-energy diet to a
degree that approached statistical significance despite a
small sample size (high-energy diet at 1.147G
0.134 ng/ml versus high-energy dietCmetformin at
0.999G0.063 ng/ml; PZ0.11). The influence of
metformin on C-peptide levels was anticipated, as
metformin is known to reduce gluconeogenesis and
serum glucose levels that would have an indirect effect
on insulin secretion. Insulin tolerance tests (Fig. 2C)
showed that following the initial drop in blood glucose,
those mice on the high-energy diet had significantly
reduced ability to maintain a lowered blood glucose
concentration 45 min after the insulin injectionwww.endocrinology-journals.org 851
C Algire et al.: Impact of metformin and diet on tumor growthcompared with those mice on the control diet (control
diet blood glucose at tZ45: 3.9G0.10 mmol/l versus
high-energy diet blood glucose at tZ45: 7.7G
0.71 mmol/l; P!0.0001; Fig. 2C). The mice on the
high-energy diet with metformin had significantly
improved insulin tolerance compared with those on
the same high-energy diet without metformin. These
animals were able to maintain a lowered blood glucose
concentration at 45 min following insulin injection
(high-energy dietCmetformin blood glucose at tZ45:
5.47G0.43 mmol/l versus high-energy blood glucose
at tZ45: 7.7G0.71 mmol/l; P!0.05). However,
metformin did not completely reverse the effects of
the high-energy diet. Metformin had no effect on the
insulin tolerance of those mice on the control diet
(control dietCmetformin blood glucose at tZ45 min:
4.45G0.34 mmol/l versus control diet blood glucose,
3.9G0.10 mmol/l; PO0.05).Effect of diet and metformin on tumor growth
Tumor growth curves are shown in Fig. 3. In keeping
with a prior report (Yakar et al. 2006), the high-energy
diet was associated with increased tumor growth
(tumor size of 2056G240 mm3 for high-energy diet
versus 1313G204 mm3 for control diet at day 17;




























Figure 3 Impact of diet and metformin on tumor growth in vivo.
Tumors were first detected 11 days after injection of H59 cells.
The high-energy diet was associated with increased tumor
growth rate and overall tumor size compared with tumors in
mice on the control diet (tumor size of 2056G240 mm3 for high-
energy diet versus 1313G204 mm3 for control diet at day 17;
*P!0.0001). Metformin was given in the drinking water of mice
at a dose of 50 mg/kg body weight per day for 3 weeks prior to
injection of H59 carcinoma. Metformin treatment was associ-
ated with reduced overall tumor size in those mice on the high-
energy diet (tumor size of 1231G207 mm3 for high-energy
dietCmetformin versus 2056G240 mm3 for high-energy diet at
day 17; **P!0.0001). Metformin did not have an effect in those
mice on the control diet (tumor size of 1537G114 mm3 for
control dietCmetformin versus 1313G204 mm3 for control diet
at day 17; PO0.05).
852significantly decrease tumor growth rate and tumor
size in mice on the high-energy diet (tumor size of
1231G207 mm3 for high-energy dietCmetformin
versus 2056G240 mm3 for high-energy diet at day
17; P!0.0001). There was no statistically significant
effect of metformin on tumor growth in those mice
on the control diet (tumor size of 1537G114 mm3 for
control dietCmetformin versus 1313G204 mm3
for control diet at day 17; PO0.05).Metformin alters signaling in tumors
Our prior work demonstrated that in vitro growth
inhibition of cancer cells by metformin involves the
activation of the AMPK pathway (Zakikhani et al.
2006). In order to determine whether this mechanism
occurs in the in vivo models, we measured AMPK
activation in the normal and neoplastic tissue.
Metformin activated AMPK in the neoplastic tissue,
as shown by western blot using a phospho-specific
antibody against AMPK Thr172 (Fig. 4A). However,
because we observed no significant effect of metformin
on tumor growth for mice on the control diet, we
hypothesized that metformin attenuated tumor growth
through lowering of insulin levels, in addition to any
effect on AMPK.
In support of this hypothesis, there was increased
tyrosine phosphorylation of the insulin receptor, an
indicator of insulin receptor activation, in tumor tissue
from mice on the high-energy diet compared with
tumor tissue from mice on the control diet (Fig. 4B). In
addition, among mice on the high-energy diet,
metformin administration decreased insulin receptor
tyrosine phosphorylation intensity by 38%, compared
with mice on the same high-energy diet without
metformin. The inhibitory effect of metformin on
insulin receptor phosphorylation was smaller in
magnitude than the stimulatory effect of the high-
energy diet (Fig. 4B). We also examined downstream
signaling through insulin receptor substrate 1 (IRS-1).
Under conditions of insulin resistance, serine phos-
phorylation of IRS-1 is increased through negative
feedback regulation (Giraud et al. 2004). However, not
all serine phosphorylation sites are inhibitory; the
phosphorylation site 302 is known to be associated
with increased insulin receptor signaling and increased
nutrient availability (Giraud et al. 2004). We found
elevated serine 302 phosphorylation of IRS-1 in tumors
from mice on the high-energy diet compared to
tumors from mice on the same high energy with
metformin, as well as tumors taken from both groups
on the control diet.www.endocrinology-journals.org
Endocrine-Related Cancer (2008) 15 849–855In the context of the finding that metformin acted as
an inhibitor of tumor growth under conditions where
the high-energy diet stimulated tumor growth, these
results suggest that in vivo the mechanism by which
metformin reduces tumor proliferation involves sup-
pression of insulin levels and subsequent reduction of
insulin signaling, rather than being entirely attributable
to AMPK activation.Discussion
There is increasing interest in potential roles of the
biguanide metformin or other AMPK activators (Cool
et al. 2006) in cancer treatment and prevention. We
confirmed the results of a prior report (Yakar et al.
2006) showing that a high-energy diet is associated


























































































































































www.endocrinology-journals.orgLLC1 model. We also observed that metformin almost
completely attenuated the effect of high-energy diet on
tumor growth, while having no significant impact on
tumor growth of animals on the control diet.
Prior experiments provide evidence that AMPK
activation by metformin leads to growth inhibition of
cancer cells in vitro (Zakikhani et al. 2006). We
studied the in vivo effects of metformin on tumor
growth and employed a model that allowed us to make
observations under standard metabolic conditions and
also under conditions of dietary-induced hyperinsuli-
nemia and systemic insulin resistance. This model
allowed us to study tumor growth in the context of the
metabolic characteristics of metformin-treated patients
with type II diabetes, where there is early epidemio-
logic evidence of possible anti-neoplastic activity of
the drug (Evans et al. 2005, Bowker et al. 2006).
The finding that metformin attenuates the stimu-
latory effect of a high-energy diet on tumor growth in
this model, but has no effect on baseline tumor growth
is intriguing. The signaling data provide evidence that
metformin at the dose and route we employed activates
AMPK in neoplastic tissue in animals on both a control
and a high-energy diet. However, metformin-induced
growth inhibition of tumors was only observed in
animals on the high-energy diet, thus suggesting that
mechanisms other than APMK activation may be
involved. We observed by western blotting, using aFigure 4 Effect of diet and metformin on signaling in C57
neoplastic tissues. (A) Tumor tissue was analyzed by western
blot and immunoprecipitation. We observed increased phos-
phorylation of AMPK at Thr172 in tumor tissue from those mice
on the control diet and the high-energy diet that received
metformin (relative intensity of control diet versus control dietC
metformin; P!0.005; high-energy diet versus high-energy
dietCmetformin; P!0.05). (B) For insulin receptor phos-
phorylation, tumor tissue was analyzed by immunoprecipitation
of the insulin receptor and western blotting with an anti
phospho-tyrosine antibody. The high-energy diet (HED) was
associated with increased insulin receptor activation as shown
by elevated tyrosine phosphorylation of the insulin receptor in
tumor tissues of mice in this group (relative intensity of high-
energy diet versus control diet P!0.0001). Metformin attenu-
ated the increased insulin receptor activation in tumors from
mice on the high-energy diet (relative intensity of high-energy
diet versus high-energy dietCmetformin, P!0.05), but not in
the tissues from mice on the control diet. IRS-1 Ser 302 activity
was measured using a site-specific antibody. We found
elevated signaling through IRS-1 in those mice on the high-
energy diet compared with that on the control diet (relative
intensity high-energy diet versus control diet P!0.001),
indicating increased insulin receptor signaling and increased
nutrient availability. The increased IRS-1 signaling was
attenuated in the high-energy diet group that received
metformin (relative intensity high-energy diet versus high-
energy dietCmetformin; P!0.001). b-Actin was measured as a
loading control.
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insulin receptors are expressed by lewis lung LLC1
cells. Furthermore, the tumor tissue from mice on the
high-energy diet was found to have elevated insulin
receptor activation as shown by increased tyrosine
phosphorylation of insulin receptor, compared with
tumor tissue from mice on the control diet. This occurs
in the context of the known association of elevated
insulin levels with obesity and excess caloric intake
(Shuldiner et al. 2001) and the elevated insulin levels
and weight associated with the high-energy diet in the
model we employed. It is possible that the anti-
neoplastic action of metformin in this model involves
its well-known action as an insulin-lowering agent,
leading to a reduction in insulin signaling in tumor
cells, rather than the in vitro mechanism of AMPK
activation. Thus, our observations are compatible with
the increasingly accepted view (Shaw et al. 2005) that
metformin reduces insulin levels in hyperinsulinemic
states by a mechanism involving reduced hepatic
glucose output and do not support the possibility that
metformin lowers insulin levels by enhancing insulin
receptor signaling (Holland et al. 2004). Our results
therefore imply that in hosts with diet-induced insulin
resistance, neoplastic tissue is not necessarily also
insulin resistant to the same degree, if at all.
Our study is not the first report of in vivo anti-
neoplastic activity of metformin. A recent paper
(Buzzai et al. 2007) demonstrated in vivo inhibition
of growth of HCT-116 colon cancer cells, but used
doses approximately five times larger than those we
employed. In that study, anti-neoplastic activity was
observed to be restricted to a p53K/K HCT-116
variant, but diet was not treated as a variable and
insulin receptor activation was not evaluated.
There is convincing epidemiological evidence that
obesity is associated with increased cancer mortality
(Calle et al. 2003, Ogden et al. 2006). However, while
there is clear laboratory evidence for an inhibitory
effect of caloric restriction on tumor growth (Carroll
1975), there are few in vivo models of adverse effects
of excess dietary intake or obesity on cancer behavior.
The H59 syngeneic tumor model we employed appears
to be useful for studies of excess energy intake on
tumor behavior (Yakar et al. 2006). The correlation of
excess energy consumption with increased insulin
receptor phosphorylation in neoplastic tissue suggests
that insulin is a mediator of the dietary effect in our
model and also a mediator of the association of obesity
with adverse outcome seen in population studies (Calle
et al. 2003). However, there are many other candidate
mediators of the effect of excess energy intake or
obesity on tumor growth, including leptin and/or other854adipokines, elevated free fatty acids, or altered levels
of circulating carbohydrates. In particular, further work
investigating the effects of diet and metformin on
insulin-like growth factor-I signaling is necessary.
Recent population studies have linked serum C-peptide
levels (a marker for insulin secretion) to adverse cancer
prognosis (Ma et al. 2006). These data, together with
evidence for the expression of insulin receptors on
tumor cells (Papa & Belfiore 1996, Belfiore 2007),
represent further circumstantial evidence consistent
with insulin as a mediator of the adverse effect of
excess energy intake on cancer prognosis. While it
would be interesting to investigate the effects of other
pharmaceuticals for treating insulin resistance, such as
thiazolidnediones; these PPARg activators are known
to have anti-neo-plastic effects secondary to the effect
on insulin signaling (Grommes et al. 2004).
The finding that the inhibitory effect of metformin on
tumor growth was restricted to animals on the high-
energy diet suggests that any benefits of this drug
in reducing cancer aggressiveness may be restricted to
a metabolically defined subset of cancer patients.
The definition of this subset is an important topic
for further translational research. Serum markers
of hyperinsulinemia may be more useful than
simple body morphometry, due to the existence of
the so-called ‘normal weight, metabolically obese’
individuals (St-Onge et al. 2004, Conus et al. 2007).
Clinical trials of metformin in cancer treatment have
been proposed, and it will be important that these trials
are evaluated in a way that is stratified for baseline
metabolic profile.Acknowledgements
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Endocrine-Related Cancer (2010) 17 351–360Metformin blocks the stimulative effect
of a high-energy diet on colon carcinoma
growth in vivo and is associated with
reduced expression of fatty acid synthaseCarolyn Algire, Lilian Amrein1, Mahvash Zakikhani1,
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(Correspondence should be addressed to M Pollak; Email: michael.pollak@mcgill.ca)AbstractThe molecular mechanisms responsible for the association of obesity with adverse colon cancer
outcomes are poorly understood. We investigated the effects of a high-energy diet on growth of an
in vivo colon cancer model. Seventeen days following the injection of 5!105 MC38 colon
carcinoma cells, tumors from mice on the high-energy diet were approximately twice the volume of
those of mice on the control diet. These findings were correlated with the observation that the high-
energy diet led to elevated insulin levels, phosphorylated AKT, and increased expression of fatty
acid synthase (FASN) by the tumor cells. Metformin, an antidiabetic drug, leads to the activation of
AMPK and is currently under investigation for its antineoplastic activity. We observed that
metformin blocked the effect of the high-energy diet on tumor growth, reduced insulin levels, and
attenuated the effect of diet on phosphorylation of AKT and expression of FASN. Furthermore,
the administration of metformin led to the activation of AMPK, the inhibitory phosphorylation of
acetyl-CoA carboxylase, the upregulation of BNIP3 and increased apoptosis as estimated by poly
(ADP-ribose) polymerase (PARP) cleavage. Prior work showed that activating mutations of PI3K
are associated with increased AKT activation and adverse outcome in colon cancer; our results
demonstrate that the aggressive tumor behavior associated with a high-energy diet has similar
effects on this signaling pathway. Furthermore, metformin is demonstrated to reverse the effects
of the high-energy diet, thus suggesting a potential role for this agent in the management of a
metabolically defined subset of colon cancers.Endocrine-Related Cancer (2010) 17 351–360Introduction
Many population studies (for example Pietinen et al.
(1999), Calle et al. (2003), Meyerhardt et al. (2003,
2007), Dignam et al. (2006) and Moon et al. (2008))
provide evidence that excess energy intake and/or
obesity is associated with increased risk of colorectal
cancer and/or with poor prognosis of this disease.
Further epidemiological evidence (Ma et al. 2004,
Wei et al. 2005, 2006, Wolpin et al. 2009) suggests
the hypothesis that one of the underlying mechanisms
involves stimulation of malignant proliferation by
insulin. This is plausible in the context of theEndocrine-Related Cancer (2010) 17 351–360
1351–0088/10/017–351 q 2010 Society for Endocrinology Printed in Greatwell-known association of obesity with hyperinsuline-
mia (Cahill 1971) and with insulin receptor expression
by transformed cells (Frasca et al. 1999, Becker et al.
2009), reviewed in Pollak (2008).
Metformin, an antidiabetic drug, lowers the elevated
insulin levels found in type II diabetes by inhibiting
gluconeogenesis and hepatic glucose output, which in
turn reduces blood glucose levels and results in a
secondary decline in insulin levels (Shaw et al. 2005).
Retrospective studies involving cancer outcomes
among diabetic patients receiving metformin therapy
have provided preliminary evidence that this
compound favorably influences cancer outcomesBritain
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C Algire et al.: Metformin blocks expression of FASN in vivo(Evans et al. 2005, Bowker et al. 2006). The drug acts
by impairing oxidative phosphorylation, which
increases the intracellular AMP/ATP ratio, leading
to the activation of the LKB1–AMPK signaling
pathway (Leverve et al. 2003, Buzzai et al. 2007).
In hepatocytes, this pathway has a special role in the
regulation of gluconeogenesis, whereas in neoplastic
cells, AMPK activation changes gene expression
patterns in ways that result in decreased proliferation
(Wang & Guan 2009). The ability of metformin to
activate AMPK depends on the presence of functional
LKB1 (Shaw et al. 2005) and in vitro, in cells where the
LKB1–AMPK signaling pathway is intact, metformin-
induced AMPK activation is known to decrease protein
synthesis and cell proliferation (Zakikhani et al. 2006,
2008, Dowling et al. 2007), and we have shown this to
be the case for colon cancer cells (Zakikhani et al.
2008). Thus, metformin may reduce neoplastic
proliferation by indirect (insulin lowering) actions
and/or direct (activation of AMPK in transformed
cells) mechanisms. A prior study (Tomimoto et al.
2008) demonstrated that metformin suppresses polyp
formation in ApcMin/Cmice, but effects of the drug on
colon cancer growth in vivo in the context of obesity
and/or excess energy intake have not yet been reported.
In this study, we investigated the effects of
metformin on the in vivo growth of MC38 colon
carcinoma. Bearing in mind that the epidemiological
evidence for the antineoplastic activity of metformin
was obtained from type II diabetic populations who
tend to be hyperinsulinemic and obese, we chose to
carry out in vivo studies of metformin in mice provided
with either a high-energy diet that induced weight gain
and elevated insulin levels, or a control diet. We also
explored the relationship between expression of fatty
acid synthase (FASN) and diet and/or metformin
administration. FASN catalyzes the biosynthesis of
long-chain fatty acids from acetyl-CoA and malonyl-
CoA. The fatty acids generated by FASN are essential
constituents of all biological membrane lipids and are
important substrates for energy metabolism. In well-
nourished mammals, FASN activity and expression in
untransformed cells are low due to ample supply of
fatty acids derived from diet. In contrast, neoplastic
cells continue to utilize FASN and display high levels
of constitutive endogenous fatty acid synthesis, even in
the presence of dietary fatty acids. Overexpression and
hyperactivity of FASN are a common characteristic of
aggressive malignancies, and inhibition of FASN by
siRNA has been shown to induce apoptosis in
breast cancer cells (Bandyopadhyay et al. 2006).
Furthermore, FASN expression by colorectal cancers
has been described as an adverse prognostic factor in352obese patients (Ogino et al. 2008), and thus, it is
possible that metabolic hormones that are influenced
by excess energy intake may be involved in regulating
the expression of FASN in neoplastic cells.Materials and methods
Animal work
All experiments performed were approved by the
McGill University Animal Care and Handling
Committee. Forty-eight male C57BL/6 mice purchased
from Charles River (Saint-Constant, QC, Canada) at
5–6 weeks of age were housed 4–5 per cage and put on
either a control or high-energy diet ad libitum for 17
weeks. Diets were purchased from Harlan Teklad
(Madison, WI, USA). The control diet was TD 2016
and consisted of 16% protein, 3.5% fat, and 60%
carbohydrate, and this diet provided 3.3 kcal/g
consumed. The high-energy diet was TD 95 217
and consisted of 18.8% protein, 39.8% fat (lard), and
41.4% carbohydrate, and this diet provided 4.3 kcal/g
consumed. During the first 12 weeks on the diets, there
were 24 mice on the control diet and 24 mice on the
high-energy diet.
Metformin
Following 12 weeks on the experimental diets, a
subgroup of mice from each dietary group (nZ12
mice) was given metformin in the drinking water.
Metformin was administered at a dose of 50 mg/kg
body weight per day. It was assumed that the mice
drank 7.0 ml of water per day, and pilot experiments
have shown that mice do not consume less water
when metformin is added. Metformin was dissolved in
200 ml making for a concentration of 0.28 mg/ml for
mice on the high-energy diet and 0.23 mg/ml for mice
on the control diet. The dose of metformin was
adjusted biweekly for changes in body weight.
Hormone measurement
Blood was collected in heparinized capillary tubes
following 17 weeks on the diet (5 weeks with or
without metformin). Plasma was used for insulin
(Millipore, Billerica, MA, USA), insulin-like growth
factor 1 (IGF1; R and D Systems, Minneapolis, MN
USA), and leptin (Millipore) ELISAs.
Tumor growth
MC38 cells were generously donated by Dr Pnina
Brodt. Cells were cultured in flasks and in 10%







Control diet 34.66 ± 0.61
Control diet + metformin 32.41 ± 0.66
High energy diet 40.17 ± 0.97







































































Figure 1 Effects of diet and/or metformin on weight and
serum insulin, IGF1, and leptin levels. Mice were separated
into four groups: control dietGmetformin or high-energy
dietGmetformin. The diets were maintained for 17 weeks.Those
groups with metformin received metformin in the drinking water
at a concentration of 50 mg/kg per day for the last 5 weeks on the
respective diets. The mice on the high-energy diet weighed
significantly more than those mice on the control diet. Metformin
did not have a significant effect on weight for either dietary group.
CD, control diet; CDCM, control dietCmetformin, HED, high-
energy diet and HEDCM, high-energy dietCmetformin.
(A) Weight prior to tumor injection; (B) insulin, *P!0.001,
**P!0.05; (C) IGF1, *P!0.001; (D) leptin; PZ0.0008.
Endocrine-Related Cancer (2010) 17 351–360trypsinized, counted, and re-suspended in PBS prior to
injection. Mice were injected s.c. with 5!105 MC38
colon carcinoma cells, a syngeneic tumor cell line.
Tumors were palpable in the majority of the mice
8 days following tumor inoculation. Tumor growth
was measured every other day with electronic calipers
(Lee Valley Tools, Ottawa, ON, Canada).
Protein extraction and immunoblotting
Tumor tissue was removed immediately after killing
and was snap frozen in liquid nitrogen. Tissue
was homogenized in lysis buffer (20 mM HEPES
buffer, 1% Triton X-100, 150 mM NaCl, 0.02% sodium
azide, 60 mM b-glycerophosphate, 1 mM sodium
vanadate, 1 mM dithiothreitol, 1 Roche complete
protease inhibitor tablet, and 5 ml of 5 mM pepstatin
A per 50 ml lysis buffer), and 100 mg of tissue was
subjected to electrophoresis in denaturing 8–10%
SDS-PAGE. Primary antibodies for p-AKT, AKT
total, p-AMPK, AMPK total, b-actin, BNIP3, poly
(ADP-ribose) polymerase (PARP), FASN, and acetyl-
CoA carboxylase total were purchased from Cell
Signaling Technologies (Danvers, MA, USA). The
antibody for p-acetyl-CoA carboxylase was purchased
from Millipore (Concord, MA, USA), and the antibody
for SREBP-1 as well the secondary antibodies was
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). All primary antibodies were diluted 1:500,
and the secondary antibody was diluted 1:5000.
Westerns were developed using Western Lightning
Plus-ECL (Perkin-Elmer, Waltham, MA, USA), and
density of the western blots bands was determined by
Scion Image.
Statistical analyses
For tumor data, prior to statistical analysis, data were
square-root transformed to satisfy the assumptions of
analysis. Statistical significance was evaluated using the
GLM procedure. A one-way ANOVA was used to
determine whether there was significant difference among
all treatment groups. Additionally, Student–Newman–
Keuls test for multiple pairwise comparisons of means
and least-squares means multiple unpairwise comparisons
of means (LSMEANS statement with Bonferroni correc-
tion) were applied. All statistical analyses were performed
using Statistical Analysis System software, version 9.1.3
(SAS Institute, Cary, NC, USA), with the P values!0.05
considered significant.
For direct comparison between two groups (such as
comparing dietary effect on insulin levels), Student’s
t-test was used in the Microsoft Excel Program, and
error bars represent the S.E.M.www.endocrinology-journals.orgResults
Influence of diet and metformin on body weight
and circulating insulin, IGF1, and leptin levels
Figure 1A shows the effect of diet, and metformin, on
weight gain in our model. The weights shown were
measured following 17 weeks on the diets, including





























Figure 2 Effect of diet and metformin on MC38 colon cancer
growth in vivo. Following 17 weeks on the experimental diets
(with or without 5 weeks of metformin), 5!105 MC38 colon
carcinoma cells were injected s.c., and tumor growth was
observed for 17 days. This shows that mice on the high-energy
diet had significantly larger tumor volume compared to mice on
the control diet (*PZ0.003). Metformin significantly attenuated
the stimulative effect of the high-energy diet on tumor growth
in the high-energy dietCmetformin group (**PZ0.005), while
having no significant effect on the tumor growth of mice in the
control dietCmetformin group.
C Algire et al.: Metformin blocks expression of FASN in vivoThe high-energy diet was sufficient to induce signi-
ficant weight gain compared to the control diet
(control diet: 34.66G2.02 g versus high-energy diet:
40.17G3.22 g; P!0.0001, nZ12/group). Metformin
was given in the drinking water at 50 mg/kg per day
for 5 weeks. Although metformin may cause minor
gastro-intestinal distress or appetite suppression
(Kirpichnikov et al. 2002), in our model, there were
no adverse effects of metformin at the dose employed.
The mice that were administered metformin in the
drinking water did not have body weight that differed
significantly from the mice in the same dietary group
that did not receive the drug.
Elevated levels of insulin and IGF1 often are seen
in the context of excess energy intake, obesity, and
associated metabolic diseases, and are also known to
negatively influence cancer outcomes (Pollak 2009,
Wolpin et al. 2009). Insulin, IGF1, and leptin levels
were measured by ELISA using blood taken from the
mice following 17 weeks on the diets, with or
without metformin treatment for the final 5 weeks.
As expected, mice on the high-energy diet had
significantly higher insulin levels compared to mice
on the control diet (Fig. 1B), consistent with diet-
induced hyperinsulinemia (control diet: 2.80
G0.34 ng/ml versus high-energy diet: 8.14G0.77
ng/ml; *P!0.0001, nZ12/group). Metformin reduced
elevated insulin in hyperinsulinemic mice, but had
little effect on the insulin levels of mice on the
control diet (high-energy diet: 8.14G0.77 ng/ml
versus high-energy dietCmetformin: 5.45G0.97
ng/ml; **P!0.05, nZ12/group). Figure 1C shows
the effect of the high-energy diet on IGF1 levels
(control diet: 559.10G14.25 ng/ml versus high-energy
diet: 716.80G22.45 ng/ml; *P!0.0001). Clinically,
metformin is not considered to have important effects
on IGF1 level, but there was evidence for an
IGF1-lowering effect of metformin in an experimental
model that used high doses of the drug (Phoenix et al.
2009). In our model, we observed no significant
effect of metformin on IGF1 in either dietary group.
We observed a greater than twofold increase in
leptin levels (Fig. 1D) in mice on the high-energy
diet compared to mice on the control diet (control diet:
11.00G2.04 ng/ml versus high-energy diet: 27.00
G3.40 ng/ml; *PZ0.0008), but metformin had no
significant effect on the leptin levels. Recent reports
(Cirillo et al. 2008) have suggested that leptin
signaling may play a role in tumorigenesis of tumor
cells that express the leptin receptor; however, the
MC38 cell line is null for the leptin receptor, and
treatment of this cell line with leptin did not affect cell
growth as measured by MTT assay (data not shown).354Influence of diet and metformin on
in vivo tumor growth
In keeping with a prior report (Yakar et al. 2006), we
observed a potent stimulative effect of the high-energy
diet on MC38 tumor growth (final tumor volume:
control diet: 1186G99 mm3 versus high-energy diet:
2073G319 mm3; *PZ0.003) (Fig. 2). Metformin signi-
ficantly attenuated the effect of the high-energy diet on
tumor growth, but interestingly had no significant effect
on tumor growth of mice on the control diet (tumor
volume at day 17 following injection: high-energy diet:
2073G319 mm3 versus high-energy dietCmetformin:
1275G223 mm3; **PZ0.005). These results indicate
that the growth inhibitory activity of metformin for
MC38 colon cancer is strongly influenced by the
metabolic status of the host.
Effect of diet and metformin on intracellular
signaling pathways
AMPK
Activation of AMPK was measured by western blot of
AMPK phosphorylated at Thr172. We observed (Fig. 3)
increased phosphorylated AMPK in the tumor tissue
from mice administered metformin, indicating that the
dose and route of administration were sufficient to
allow the drug to act as an indirect AMPK activator in
transformed cells, as described in vitro (Zakikhani
et al. 2008), and in vivo in liver (Shaw et al. 2005).
AMPK activation stimulates many downstream














































































Figure 3 Metformin leads to activation of AMPK and
phosphorylation of acetyl-CoA carboxylase. Western blot
analyses show that the addition of metformin was sufficient to
activate AMPK in the tumor tissue, as shown by increased
phosphorylation at Thr172. Activation of AMPK results in the
inhibitory phosphorylation of acetyl-CoA carboxylase at Ser79.
We also observed this downstream effect of AMPK activation
in the tumor tissue taken from mice in the metformin groups:
phosphorylation at Ser79 was significantly higher in the
metformin group compared to the parental dietary group
indicating inhibition of the rate-limiting step in de novo fatty acid
synthesis. CD, control diet; CDCM, control dietCmetformin;
HED, high-energy diet; HEDCM, high-energy dietCmetformin.
Endocrine-Related Cancer (2010) 17 351–360conserve ATP. To confirm that metformin-induced
activation of AMPK was associated with downstream
pathway activation, we measured phosphorylation
status of the AMPK substrate acetyl-CoA carboxylase
at its inhibitory Ser79 site, and observed increased
phosphorylation in the presence of metformin.
When active, acetyl-CoA carboxylase catalyzes the
ATP-dependent carboxylation of acetyl-CoA to
malonyl-CoA. This step is the rate-limiting step in
the de novo fatty acid synthesis pathway, indicating
that metformin can act to suppress the formation of
malonyl-CoA and de novo fatty acid synthesis.
Suppression of anabolic pathways is in keeping with
the expected consequences of AMPK activation.www.endocrinology-journals.orgAKT
We observed a 60% increase in p-AKT-Ser473 in tumor
tissue taken from mice on the high-energy diet
compared to tumor tissue taken from mice on the
control diet (Fig. 4A), which we attribute to increased
signaling through insulin receptors present on the
MC38 colon cancer cells (Fig. 4B). Metformin
attenuated the effect of diet on AKT signaling in
tumors of mice on the high-energy diet, consistent with
the observed effects of the drug on insulin levels.
We observed the same trend (Fig. 4A) in levels of
cleaved SREBP-1, a transcription factor downstream
of AKT. SREBP-1 is a transcription factor that
mediates the expression of enzymes involved in lipid
and cholesterol homeostasis (Yokoyama et al. 1993).
Our observation indicates that diet-induced changes in
AKT phosphorylation are of sufficient magnitude to
have an impact on AKT targets. We also observed a
significant reduction in cleaved SREBP-1 in tumors of
mice that were administered metformin, independent
of dietary group.
There is considerable evidence that FASN plays a
key role in the lipogenic phenotype of many human
cancers (Menendez & Lupu 2007). Our observation
that a high-energy diet increases FASN levels twofold
in MC38 colon cancers compared to that seen in
tumors of animals on the control diet (Fig. 4C)
represents the first evidence that macronutrient intake
by the host can influence FASN expression in
neoplastic tissue. In vitro results (Fig. 4D) show that
insulin, more than IGF1, upregulates FASN expression
by MC38 cells, suggesting that insulin-stimulated
AKT activation may upregulate FASN in vivo.
Metformin, shown in Fig. 2 to block the stimulative
effect of a high-energy diet on tumor growth, was also
observed to completely reverse the stimulative effect of
the high-energy diet on FASN expression in tumor
tissue (Fig. 4C). This novel action of metformin on
neoplastic cells is plausible given the observed
decrease in mature SREBP-1 and that inhibition of
energy-consuming synthesis of macromolecules is a
well-known consequence of AMPK activation (Wang
& Guan 2009). Given that there is a rationale for FASN
inhibition for cancer treatment (Menendez & Lupu
2007), it is possible that this consequence of metformin
action contributes to its antineoplastic activity, particu-
larly where baseline FASN levels are high.Metformin induces apoptotic proteins in vivo
It has been shown (Bandyopadhyay et al. 2006) that
BNIP3, a Bcl-2 family member and pro-apoptotic










































































































































































































Figure 4 High-energy diet leads to increased phosphorylation of AKT and increased expression of fatty acid synthase in vivo, and
insulin increased fatty acid synthase expression in vitro. (A) We observed increased phosphorylated AKT at Ser473 in the tumor
tissue taken from mice on the high-energy diet (HED) compared to tumor tissue from mice on the control diet (CD) consistent with
increased growth factor signaling. The administration of metformin significantly reduced the amount of phosphorylated AKT in
tumors of mice on the high energy diet group (HEDCM), but we observed no significant difference in the amount of phosphorylated
AKT in tumors of mice on the control dietCmetformin group (CDCM) compared to the control diet alone. Downstream of AKT, we
found elevated expression of the mature form of SREBP-1 in the tumors of mice in the high energy diet group compared to the control
diet group. Tumor tissue from mice in the metformin groups had significantly reduced expression of the mature form of SREBP-1
compared to the parental dietary groups. (B) Expression of insulin receptors on MC38 colon carcinoma cells. (C) FASN expression
was shown to be significantly higher in tumor tissue from mice on the high-energy diet, while the addition of metformin attenuated the
expression of FASN in both dietary groups. (D) MC38 cells were treated in DMEMC2% FBS with either 10 nmol insulin, 10 nmol
IGF1, or 5 mM metformin for 48 h and analyzed for expression of FASN.
C Algire et al.: Metformin blocks expression of FASN in vivois repressed. We found that the low-dose metformin
administered in our model significantly upregulated the
expression of this pro-apoptotic protein in tumors
independent of diet (Fig. 5). As PARP is a substrate of
apoptosis-inducing caspases, the amount of cleaved
PARP is used to assess the propensity of cells to
apoptosis. We used this endpoint to assess the effects of
metformin on apoptosis (Fig. 5). Metformin increased
the quantity of cleaved PARP regardless of diet.
Interestingly, the level of apoptosis assessed by the
cleaved PARP was lower in mice on the high-energy
diet than those on the control diet, and the fold
increase in cleaved PARP with the administration of356metformin was greater for mice on the high-energy
diet (10.7-fold increase) as compared to that for mice
on the control diet (3.87-fold increase). The signi-
ficance of our incidental observation of an increase
in total PARP level with the high-energy diet is under
investigation.Discussion
There are limited prior experimental data concerning
the relationship of excess energy intake to colorectal
cancer biology, despite the fact that population studies
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Figure 5 Induction of apoptotic proteins. Tumor tissue was
analyzed for expression of BNIP3 and PARP cleavage. For
PARP, the 116 and the 89 kDa bands are shown, and cleavage
was calculated as the ratio of cleaved PARP to total PARP.
BNIP3 expression was normalized to b-actin as loading control.
The data indicate that metformin administration leads to
increased BNIP3 and cleaved PARP in MC38 colon cancer
in vivo, while the high diet was associated with reduced BNIP3
and reduced cleaved PARP. CD, control diet; CDCM, control
dietCmetformin; HED, high-energy diet; HEDCM, high-energy
dietCmetformin.
Endocrine-Related Cancer (2010) 17 351–360behavior (Yakar et al. 2006). We observed, in a murine
model, that increased macronutrient intake leads to
an increase in insulin levels, an increase in AKT
activation, increased FASN and increased tumor
growth of MC38 colon carcinoma.
Furthermore, we observed that metformin attenuates
the increase in tumor growth associated with excess
energy intake, and also reversed each of the biomarker
changes observed in mice of the high energy dietary
group. Our findings concerning the effects of
metformin on signaling pathways suggest that in our
model, the drug may act on neoplastic cells by both
direct, AMPK mediated, and indirect insulin-mediated
mechanisms. As expected, metformin reduced the
high levels of insulin seen in mice consuming awww.endocrinology-journals.orghigh-energy diet. This action of metformin has been
shown to be a consequence of activation of the
LKB1–AMPK pathway in liver, which results in
decreased gluconeogenesis, decreased hepatic glucose
output, reduced circulating glucose, and a secondary
decline in insulin (Shaw et al. 2005). This correlated
with reduced AKT activation in the colon cancers in
our model, an effect which would be expected to
reduce proliferation.
Separately, we detected increased activation of
AMPK in neoplastic tissue, which is the expected
consequence of metformin acting directly on cancer
cells, as well as evidence of downstream consequences
of AMPK activation, including phosphorylation of
acetyl-CoA carboxylase. AMPK activation is known to
reduce energy consuming processes such as prolifer-
ation and protein translation (Zakikhani et al. 2006,
Dowling et al. 2007, Wang & Guan 2009), and this
could contribute to the observed reduction in tumor
growth. In order to determine if the antineoplastic
activity of metformin is attributable to direct or
indirect mechanisms, or if both are necessary, it will
be necessary to use genetic approaches involving
inactivation of the LKB1–AMPK pathway in neoplas-
tic cells, or using mice in which the indirect
mechanism of action has been rendered inoperational
by LKB1/AMPK inaction in the liver (Shaw et al.
2005). Nonetheless, the fact that we observed maximal
antineoplastic activity of metformin under conditions
of diet-induced hyperinsulinemia leads us to speculate
that the indirect mechanism, in which insulin levels are
lowered by metformin, plays an important role.
A prior model (Buzzai et al. 2007) of antineoplastic
activity of metformin in vivo provided convincing
evidence that its growth inhibitory effect is influenced
by the p53 status of the tumor, with p53-null cells
being selectively growth inhibited. The data in that
study supported the hypothesis that at the doses
employed (approximately fivefold higher than that
used in our model), the drug inhibited oxidative
phosphorylation to an extent that maintaining
cellular energy supply required an AMPK-dependent
and p53-dependent switch to autophagy in vivo and
glycolysis in vitro. In the absence of functional p53,
this switch is impaired and leads to an energy deficit
and growth inhibition. In the presence of intact p53
signaling, the neoplastic cells were not growth
inhibited by metformin because of successful meta-
bolic compensation. That model involved a cell line
with a mutant PI3K, a molecular lesion which
constitutively activates signaling pathways down-
stream of the insulin receptor. Constitutive activation
of the PI3K/AKT pathway has recently been shown to357
C Algire et al.: Metformin blocks expression of FASN in vivoconfer resistance to caloric restriction-induced growth
inhibition (which is related to caloric restriction-
induced decline in insulin level (Kalaany & Sabatini
2009). It is likely that activating PI3K mutations
also confer resistance to any antiproliferative actions
of metformin which are attributable to its systemic
insulin-lowering effect (Pollak 2009). Thus, in the
setting of high-dose metformin and an activating
PI3K mutation, dominant consequences of the
drug include metformin-induced energy stress and
AMPK–p53-dependent metabolic compensation for
survival, or in the case of defective compensation,
growth inhibition, or death. In other contexts, such as
diet induced hyperinsulinemia in vivo, metformin-
induced antiproliferative effects may be attributable to
the declines in insulin levels, reduced AKT phos-
phorylation and/or AMPK activation, and the induction
of energy-conserving pathways.
Prior work (Samuels et al. 2004, Guo et al. 2007,
Ogino et al. 2008) demonstrated that AKT activation is
an important determinant of colon cancer behavior, but
emphasized mutational activation of PI3K as a
mechanism resulting constitutive AKT signaling.
This mechanism has been estimated to operate in
approximately one-third of colon cancers (Samuels
et al. 2004). Our model demonstrates that high dietary
energy intake can activate the AKT pathway in colon
cancer cells, increase FASN expression, and accelerate
tumor growth. This shows that energy intake and/or
systemic metabolic factors may influence a subset of
colon cancers by regulating the same signaling
pathway that mediates the effects of activating somatic
mutations of PI3K. Furthermore, we present evidence
that for cancers in which tumor growth and AKT
activation are stimulated by a high-energy diet,
metformin has growth inhibitory activity, and also
reduces AKT activation and FASN expression.
AKT-induced cleavage of SREBP-1 leading to
increased production of FASN mRNA has been
shown (Porstmann et al. 2005) and depends on the
activity of mTORC1. As the cleavage of SREBP-1 is
dependent on mTORC1, our finding is consistent with
previous reports that show metformin can inhibit
signaling through mTORC1 via activation of AMPK
in neoplastic cells (Zakikhani et al. 2006). SREBP-1
is involved in the regulation of FASN, which is
responsible for the final catalytic step in fatty acid
synthesis, and which is commonly upregulated in
malignancies.
Despite the well-known association between obesity
and poor cancer prognosis (Calle et al. 2003), the
ultimate molecular mechanisms involved are yet to be
described. Cancer cells require de novo fatty acid358synthesis in order to maintain a constant supply of
lipids in a highly proliferative environment. Although
the mechanisms responsible for overexpression of
FASN in neoplastic cells are not fully understood, in
this study we show, for the first time, that the
expression of FASN can be manipulated by diet and
that insulin may play a role in both the increased tumor
growth and increased FASN expression. Elevated
serum insulin levels, a result of diet induced
hyperinsulinemia, were associated with increased
signaling through AKT, SREBP-1 and ultimately
increased expression of FASN in vivo. Furthermore,
the administration of metformin reversed the stimu-
latory effects of diet on tumor growth, including tumor
volume, AKT activation, and FASN expression. These
results are consistent with epidemiological and
experimental results that showed that metformin may
reduce cancer risk and improve cancer prognosis in
hyperinsulinemic cancer patients, and suggest that
there may be roles for metformin or related compounds
in the treatment of a subset of colorectal cancer defined
by criteria involving both host metabolic status and
molecular pathology of the tumor.Declaration of interest
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Diet and tumor LKB1 expression interact to determine sensitivity
to anti-neoplastic effects of metformin in vivo
C Algire1, L Amrein2, M Bazile2, S David2, M Zakikhani2 and M Pollak1
1E423 Segal Cancer Centre of the Jewish General Hospital, Departments of Experimental Medicine and Oncology, McGill University,
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Hypothesis-generating epidemiological research has
suggested that cancer burden is reduced in diabetics
treated with metformin and experimental work has raised
questions regarding the role of direct adenosine monopho-
sphate-activated protein kinase (AMPK)-mediated anti-
neoplastic effects of metformin as compared with indirect
effects attributable to reductions in circulating insulin
levels in the host. We treated both tumor LKB1 expression
and host diet as variables, and observed that metformin
inhibited tumor growth and reduced insulin receptor
activation in tumors of mice with diet-induced hyperinsu-
linemia, independent of tumor LKB1 expression. In the
absence of hyperinsulinemia, metformin inhibited only the
growth of tumors transfected with short hairpin RNA
against LKB1, a ﬁnding attributable neither to an effect
on host insulin level nor to activation of AMPK within the
tumor. Further investigation in vitro showed that cells with
reduced LKB1 expression are more sensitive to metfor-
min-induced adenosine triphosphate depletion owing
to impaired ability to activate LKB1-AMPK-dependent
energy-conservation mechanisms. Thus, loss of function of
LKB1 can accelerate proliferation in contexts where it
functions as a tumor suppressor, but can also sensitize
cells to metformin. These ﬁndings predict that any clinical
utility of metformin or similar compounds in oncology will
be restricted to subpopulations deﬁned by host insulin
levels and/or loss of function of LKB1.
Oncogene advance online publication, 22 November
2010; doi:10.1038/onc.2010.483
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Introduction
Metformin, a biguanide commonly prescribed for treatment
of type II diabetes, is currently being investigated with
respect to its anti-neoplastic activity. This research is
motivated in part by hypothesis-generating epidemiological
studies, which suggest that diabetic patients receiving
metformin have substantially (B40%) reduced cancer
burden compared with diabetic patients receiving other
therapies (Evans et al., 2005; Currie et al., 2009; Libby
et al., 2009; Bodmer et al., 2010; Landman et al., 2010).
Metformin and other biguanides are mild inhibitors
of complex I of the respiratory chain, and are known to
reduce adenosine triphosphate (ATP) levels and increase
the ratio of adenosine monophosphate to ATP in the
cell (El Mir et al., 2000; Owen et al., 2000; Hardie, 2006;
Dykens et al., 2008). The tumor suppressor LKB1
(Shackelford and Shaw, 2009) phosphorylates and
activates adenosine monophosphate-activated protein
kinase (AMPK) at Thr172 when the ratio of intracellular
adenosine monophosphate/ATP increases (Shaw et al.,
2004; Jones et al., 2005). Metformin-induced energy
stress can be overcome by activating the LKB1-AMPK
signaling pathway, which inhibits downstream targets,
such as mammalian target of rapamycin complex 1, to
downregulate processes that consume energy and
activate processes that generate ATP, in keeping with
the physiological role of AMPK as a key regulator of
cellular energy homeostasis (Shaw et al., 2004; Jones
et al., 2005; Hardie, 2007; Shackelford and Shaw, 2009).
In addition, an AMPK-independent, rag GTPase-
dependent pathway by which metformin inhibits mam-
malian target of rapamycin complex 1 has recently
been described (Kalender et al., 2010). By decreasing
mitochondrial ATP production, metformin can indir-
ectly activate LKB1-AMPK signaling in vitro in
transformed cells, with consequences including inhibi-
tion of protein synthesis (Dowling et al., 2007),
proliferation (Zakikhani et al., 2006, 2008) and expres-
sion of fatty acid synthase (Algire et al., 2010).
Multiple in vivo models have provided further
evidence for the anti-neoplastic activity of metformin.
For example, it has been shown that metformin
suppresses polyp formation in ApcMin/þ mice (Tomimoto
et al., 2008), inhibits in vivo growth of p53 null cancers
(Buzzai et al., 2007), attenuates tumorigenesis in
phosphatase and tensin homolog-deﬁcient mice (Huang
et al., 2008) and slows proliferation of triple-negative
breast cancer cells (Liu et al., 2009); however, these
studies did not investigate the anti-neoplastic effects of
metformin in the context of variation of dietary energy
intake or insulin levels. This issue is critical as all
epidemiological evidence for an anti-neoplastic action of
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metformin is derived from type II diabetic patients and
metformin has important endocrine effects at the whole
organism level in the setting of type II diabetes, apart
from any direct effects on neoplastic cells. These
endocrine effects are a consequence of actions of the
drug on hepatocytes, where administration of metfor-
min leads to the inhibition of gluconeogenesis (Shaw
et al., 2005), which causes a decline in glucose output
and therapeutically signiﬁcant reductions in the elevated
glucose and insulin levels seen in type II diabetics
(DeFronzo and Goodman, 1995). Shaw et al. (2005)
showed that the effects of metformin on gluconeogenesis
require the LKB1-dependent phosphorylation of AMPK;
however, a recent report (Foretz et al., 2010) suggests that
metformin-induced inhibition of gluconeogenesis is de-
pendent on the energy state within hepatocytes and is
independent of AMPK phosphorylation.
As hyperinsulinemia can stimulate in vivo growth of
certain neoplasms (Venkateswaran et al., 2007; Pollak,
2008; Novosyadlyy et al., 2010), the insulin-lowering
action of metformin may contribute to its anti-
neoplastic activity. Previous results (Algire et al., 2008)
showed that metformin attenuated tumor growth in a
murine model of type II diabetes, while having no effect
on tumor growth in mice on a control diet, thus raising
questions regarding the ‘direct’ AMPK-mediated anti-
neoplastic effects of metformin vs the ‘indirect’ insulin-
lowering actions of metformin as the mechanism by
which metformin attenuates tumor growth in in vivo
models.
In the present study, we engineered LKB1-deﬁcient
cell lines using short hairpin RNA (shRNA) against
LKB1 and studied the anti-neoplastic activity of
metformin, treating both host diet and expression of
LKB1 by neoplastic cells as variables in order to better
understand the ‘direct’ vs ‘indirect’ effects of metformin.
Results
LKB1 knockdown leads to resistance to the direct in vitro
AMPK-dependent growth inhibitory effects of metformin
Figure 1a shows that transfection of MC38 colon
carcinoma or Lewis lung carcinoma (LLC1) cells with
shRNA against LKB1 reduced the expression of LKB1.
For LKB1 shRNA, two shRNAs were used and the
results shown are from one selected colony from each
shRNA (‘F’ or ‘G’). The phosphorylation and activation
of AMPK requires the presence of active LKB1 (Shaw
et al., 2004) and previous reports (Zakikhani et al., 2006,
2008) have shown that, when LKB1 is functional,
exposure of neoplastic cells to 5mM metformin indir-
ectly leads to the activation of AMPK, resulting in
decreased cell proliferation. Following 48 h of metfor-
min exposure, we observed (Figure 1b) that both MC38
and LLC1 cells transfected with control shRNA were
growth inhibited by metformin, whereas those cells
transfected with shRNA against LKB1 (þF or þG)
were resistant to growth inhibition by the drug.
Figure 1c shows that those cells transfected with shRNA
against LKB1 (referred to as MC38-LKB1- and LLC1-
LKB1-) are resistant to AMPK activation and down-
stream phosphorylation of acetyl CoA carboxylase
compared to cells transfected with control shRNA.
These observations, with the proliferation results
(Figure 1b), indicate that LKB1 deﬁciency renders the
Figure 1 Effects of LKB1 knockdown and metformin on
proliferation and p-AMPK Thr172 in LLC1 and MC38 cells. (a)
Western blot demonstrating knockdown of LKB1 following
transfection of MC38 and LLC1 cells with ‘F’ or ‘G’ shRNAs
against LKB1. Lanes labeled MC38 and LLC1 show results for the
control cells following transfection with empty vector. (b) Cells
were treated with or without 5mM metformin for 48 h and
proliferation was assessed by MTT assay. MC38 and LLC1 were
signiﬁcantly growth inhibited by metformin (MC38: 30% growth
inhibition; *Po0.003, LLC1: 25% growth inhibition; **Po0.002)
whereas the proliferation of cells transfected with shRNA against
LKB1 was not signiﬁcantly altered by metformin. (c) p-AMPK
Thr172 and p-ACC Ser79 were assessed by western blot after cells
were treated with or without 5mM metformin for 48 h. For both
MC38 and LLC1, p-AMPK Thr172 increased following metformin
exposure, but this was attenuated in cells transfected with shRNA
against LKB1. C, control; M, metformin.
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MC38 and LLC1 cells insensitive to the direct growth-
inhibitory effects of metformin under standard tissue
culture conditions.
Tumor LKB1 expression is not essential for the in vivo
anti-neoplastic activity of metformin
A total of 60 mice were randomly assigned to either a
control or a high-fat diet at 5–6 weeks of age. Following
12 weeks on the respective diets, the mice on the high-
fat diet displayed signiﬁcantly greater weight gain
(Figure 2a) and hyperinsulinemia (Figure 2b) compared
with mice on the control diet. After mice had received
the assigned diets for 12 weeks, 2 105 MC38 colon
carcinoma cells were injected sub-cutaneously on the
left ﬂank, 2 105 MC38-LKB1- cells were injected sub-
cutaneously on the right ﬂank, and tumor growth was
observed for 17 days. Starting 24 h following tumor
injection, mice were given daily i.p. injections of either
50mg/kg metformin or vehicle control. Metformin
signiﬁcantly reduced the hyperinsulinemia observed in
the mice on the high-fat diet (high-fat diet vs high-fat
dietþmetformin: 4.92±1.30 vs 1.90±0.15ng/ml; Po0.05),
while having no signiﬁcant effect on insulin levels in the
control mice (Figure 2c).
As shown in Figures 3a and b, the high-fat diet
accelerated tumor growth compared with the control
diet, regardless of LKB1 expression (tumor size on
day 17: high fat diet¼ 1172±84mm3 vs control diet
605±76mm3, Po0.015). LKB1 expression did not
affect the tumor volume of mice on either diet (tumor
size on day 17: high-fat diet: MC38 1201±128mm3 vs
MC38-LKB1- 1143±127mm3; P¼ 0.15; control diet:
MC38 638±81mm3 vs MC38-LKB1- 572±136mm3;
P¼ 0.55).
Metformin completely attenuated the stimulatory
effect of the high-fat diet on MC38 tumor growth
(tumor size on day 17: high-fat diet: 1201±128mm3
vs high-fat dietþmetformin: 658±78mm3; Po0.02,
n¼ 15) while having no signiﬁcant effect on the growth
of MC38 tumors in mice on the control diet (Figure 3a).
Importantly, metformin attenuated MC38-LKB1-
tumor growth in mice on both the control diet and high-
fat diets (Figure 3b) (high-fat diet: 1143±127mm3 vs
high-fat dietþmetformin: 544±99mm3; Po0.001, control
diet: 572±136mm3 vs control dietþmetformin: 326±
57mm3; Po0.003), thus demonstrating that LKB1
expression by the tumor is not critical for metformin
Figure 2 Metformin attenuates diet-induced hypersinulinemia,
but has no effect in mice on a control diet. (a) Body weight of mice
given the high-fat diet for 12 weeks was increased relative to that
of mice on the control diet (*Po0.0001, n¼ 30). (b) Blood insulin
level of mice following 12 weeks on the high-fat diet was signi-
ﬁcantly higher than that of mice on the control diet (*Po0.006,
n¼ 15). (c) Following 12 weeks on the respective diets, mice
received daily i.p. injections of 50mg/kg metformin or vehicle for
16 days. Metformin had no effect on insulin levels of mice on the
control diet, but signiﬁcantly reduced the hypersinsulinemia
observed in mice on the high-fat diet (*Po0.05, n¼ 15). CD,
control diet; HFD, high-fat diet; met, metformin.
Figure 3 Effects of diet and LKB1 knockdown on the growth of
MC38 colon cancer cells in vivo. (a) In vivo tumor growth of MC38
cells transfected with control shRNA. The high-fat diet led to
signiﬁcantly increased tumor growth relative to the control diet.
For mice on the high-fat diet, metformin signiﬁcantly reduced
tumor growth (*Po0.02; n¼ 15); however, metformin had no
effect on growth of tumors of mice on the control diet. (b) In vivo
tumor growth of MC38-LKB1- cells. We observed the same
stimulatory effect of the high-fat diet on growth of MC38-LKB1- cells.
Metformin abolished the stimulatory effect of the high-fat diet on
tumor growth of MC38-LKB1- cells (*Po0.001, n¼ 15). Unlike
MC38, metformin signiﬁcantly attenuated growth of MC38-LKB1-
cells in mice on the control diet (**Po0.003).
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action in vivo. The observation that metformin inhibited
growth of MC38-LKB1- tumors in mice on the control
diet was unexpected, as this action could be attributed to
neither a reduction in insulin levels nor direct activation
of the LKB1-AMPK pathway in neoplastic cells.
Intracellular signaling analyses in vivo
The administration of metformin leads to the phosphor-
ylation of AMPK at Thr172, an event that is dependent
on the presence of active LKB1 (Shaw et al., 2004).
We measured AMPK phosphorylation in the tumor
tissue to determine whether the dose of metformin used
was sufﬁcient to activate AMPK in MC38 cells, and
to conﬁrm that LKB1 knockdown by shRNA was
sufﬁcient to prevent this action. We found elevated
p-AMPK (Figure 4a), independent of diet, in the tumors
that expressed LKB1, taken from mice that were
administered metformin.
We detected increased insulin receptor tyrosine
phosphorylation at Tyr972 in tumors taken from mice
on the high-fat diet relative to those from mice on the
control diet (Figure 4b), regardless of LKB1 expression,
consistent with the insulin levels measured in the blood.
This observation is consistent with previous reports
(Novosyadlyy et al., 2010 reviewed in Pollak, 2008) that
neoplasms can be growth-stimulated by insulin, and by
our observation that MC38 cells are mitogenically
responsive to physiological insulin concentrations
in vitro. The increased insulin receptor activation
associated with the high-fat diet was attenuated by
metformin, consistent with the insulin-lowering effects
of the drug. There was no signiﬁcant effect of metformin
on insulin levels or phosphorylation of the insulin
receptors of tumors in mice on the control diet.
A previous report (Buzzai et al., 2007) demonstrated
that metformin-induced energy stress causes neoplastic
cells to undergo autophagy in order to conserve energy,
an action that is dependent on the presence of functional
p53 and AMPK. To investigate the possibility that
AMPK-dependent autophagy may reduce energy stress
and alleviate the anti-neoplastic action of metformin
in vivo for mice on the control diet, we examined
phosphorylation of p53 at Ser15, and the autophagy
markers cleaved LC3 and Atg12 bound to Atg5. We
observed higher levels of phosphorylated p53 in tumors
from mice that were administered metformin compared
with those treated with vehicle (Figure 4c). We also
noted that metformin increased autophagy only in
tumors where LKB1 was expressed. This suggests that
LKB1/AMPK-dependent autophagy may protect tu-
mors from the energy stress induced by metformin, and
that LKB1 deﬁciency may sensitize cells to metformin-
induced energy stress in mice on a control diet. Each
tumor was also analyzed for expression of LKB1, and
we observed that following 17 days of tumor growth
in vivo, the MC38 cells continued to express the shRNA
and LKB1 was stably knocked down for the duration
of the in vivo experiment (data not shown).
LKB1- cells are sensitive to metformin under conditions
of low glucose in vitro
The observation that metformin can inhibit in vivo
growth of MC38-LKB1- tumors in mice on the control
diet suggests that a mechanism of action other than
reduction of host insulin levels or activation of the
LKB1-AMPK pathway must exist. We carried out
in vitro cell growth assays to examine possible interac-
tions between metformin, glucose concentration and
LKB1 expression in determining cell proliferation and
cell death. As shown in Figure 1, MC38 and LLC1 cells
transfected with shRNA against LKB1 are resistant to
the growth-inhibitory effects of metformin when grown
in regular DMEM medium (B25mM glucose) with
5mM metformin for 48 h. Figure 5a shows the effects of
varying glucose concentration and exposure to metfor-
min on cell number. Inhibition of MC38 and LLC1 cell
proliferation by metformin was observed, and did not
change signiﬁcantly with change in glucose concentra-
tion; however, LKB1- cells were more sensitive than the
control cells to metformin-induced growth inhibition at
low glucose concentration (2.5mM) and were resistant to
metformin at high glucose concentration (15mM)
(Figures 5a and b). These results are compatible with
previous in vitro evidence for an LKB1-dependent
growth-inhibitory action of metformin at high glucose
concentrations (Zakikhani et al., 2006, 2008) and with
the perspective that the LKB1-AMPK signaling path-
way, by inhibiting energy-consuming processes, protects
cells during periods of sub-optimal energy supply (Shaw
et al., 2004; Shackelford and Shaw, 2009).
Figure 4 Effects of diet and LKB1 knockdown on AMPK
activation, insulin receptor activation, and autophagy. (a) Phos-
phorylated AMPK at Thr172 in tumors arising fromMC38 cells was
detected following administration of daily 50mg/kg i.p. metformin,
regardless of diet, but was not observed in tumors arising
from MC38-LKB1- cells. (b) Insulin receptor activation (Tyr972) is
increased in tumors of mice on the high-fat diet, independent of
LKB1 expression. Metformin abolished the effect of the high-fat
diet on tumor insulin receptor activation. (c) Metformin adminis-
tration was associated with increased phosphorylation of p53, in
an LKB1-dependent manner, and also with LKB1-dependent
autophagy, as assessed by LC3 cleavage and Atg12-Atg5 binding.
CD, control diet; HFD, high-fat diet.
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Following the observation that LKB1- cells are
sensitive to metformin under low glucose conditions,
we investigated the effects of glucose and metformin
on cell death in vitro. Cells were treated with 5mM
metformin under conditions of high or low glucose,
and analyzed by ﬂow cytometry for Annexin IV and
7-amino actinomycin as markers of apoptosis and
necrosis, respectively. We observed an effect of metfor-
min on cell death primarily through necrosis, and this
effect was dependent on LKB1 expression. Figure 5c
shows that treatment with metformin led to a 30%
increase in necrotic MC38 cells, whereas MC38-LKB1-
showed a 75% increase in necrosis when treated with
metformin for 72 h. Figure 5d shows the same trend
in LLC1 cells. LLC1 cells treated with metformin displayed
an B5% increase in necrosis, whereas LLC1-LKB1-
cells displayed 45 and 54% increase in cell death for cells
transfected with shRNA F and G, respectively. These
results were observed at low glucose concentrations; we
did not observe an effect of metformin on cell death
when cells were cultured in high glucose, regardless of
LKB1 expression. Additional ﬂow cytometry data are
available in Supplementary Figures 1a and 1b.
Metformin increases glucose consumption and lactate
production in MC38 and LLC1 cells
It has been shown that cells treated with metformin
increase glucose consumption, an action that is depen-
dent on AMPK (Buzzai et al., 2007). In order
to determine whether LKB1 expression had an effect
on increased glucose consumption, we treated cells with
5mM metformin in either low glucose (2.5mM) or high
glucose (15mM) concentrations for 48 h. As shown in
Figure 6a, when MC38 cells were treated with metfor-
min, we observed a signiﬁcant increase (greater than
twofold) in glucose consumption at both glucose
concentrations. In contrast, in MC38-LKB1- cells, we
observed a minimal increase in glucose consumption at
both glucose concentrations. This was true for both
MC38þF and MC38þG cell lines. We observed the
same results in both the LLC1 cells and the LLC1-
LKB1- cells (Figure 6b). In LLC1 cells, we observed a
greater effect of glucose concentration on basal glucose
uptake than was observed with MC38; however, the fold
increase in glucose consumption with metformin treat-
ment was the same for both cell lines. Data shown in
Figures 6c and d reveal increased lactate production by
both MC38 and LLC1 cells when exposed to metformin,
suggesting increased glycolysis when taken together with
the results of the glucose consumption assays shown in
Figures 6a and b. This would be expected to compensate
in part for the decreased ATP production due to the effect
of metformin on oxidative phosphorylation; however,
LKB1- cells show a small increase in lactate production,
indicating less effective upregulation of glycolysis in an
attempt to compensate for metformin-induced energy
stress.
LKB1 expression inﬂuences cellular ATP levels following
metformin exposure
Consistent with previous data demonstrating that
biguanides reduce mitochondrial ATP production
Figure 5 LKB1 knockdown leads to sensitivity to metformin in vitro under conditions of low glucose. Bars represent cell number in
the presence of metformin as a percentage of cell number in the absence of metformin. (a) MC38 cells were growth inhibited by
metformin at both glucose concentrations. Both MC38-LKB1- cell lines were more sensitive than MC38 cells to metformin at low
glucose concentrations (MC38 vs MC38þF: *Po0.03; MC38 vs MC38þG: **Po0.05). The MC38-LKB1- cells were resistant to
metformin at high glucose concentrations. (b) LLC1 cells were also growth inhibited by metformin at both glucose concentrations;
however, LLC1þF and LLC1þG were more sensitive to metformin under conditions of low glucose (LLC1 vs LLC1þF: *Po0.02;
LLC1 vs LLC1þG: **Po0.02) and were resistant to metformin in high glucose. (c, d) MC38 cells displayed a modest (30%) increase
in cell death when treated with metformin, whereas MC38-LKB1- cells displayed nearly 75% increase in cell death (MC38 vs
MC38þF; *Po0.002; MC38 vs MC38þG: **Po0.001). Metformin increased cell death by 5% in LLC1, and by 35% and 49% for
LLC1þF and LLC1þG, respectively (LLC1 vs LLC1þF: *Po0.02; LLC1 vs LLC1þG: **Po0.001). At high glucose, metformin
had no effect on cell death.
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(Dykens et al., 2008), we observed decreased cellular
ATP concentration with metformin exposure; however,
we observed an important inﬂuence of LKB1 expression
on this effect. Following 48-h exposure to 5mM
metformin, bothMC38 and LLC1 cells showed a signiﬁcant
decrease in ATP of 40–50% under both low and high
glucose conditions (Figure 7). These results are con-
sistent with the action of metformin as a mild inhibitor
of complex I of the respiratory chain and with our
observations that metformin treatment leads to AMPK
phosphorylation in these cells (Figure 1c). The magni-
tude of the decrease in ATP observed was not dependent
on glucose concentration in either cell line. In LKB1-
cells, we observed a substantial decrease in ATP when
cells were cultured at low glucose (B80% reduction in
MC38-LKB1- and 90% in LLC1-LKB1-). Under
conditions of 15mM glucose, we did not observe a
decrease of the same magnitude as in conditions of low
glucose. In MC38-LKB1- cells (for both MC38þF and
MC38þG) we observed only a 15% decrease in ATP,
whereas in LLC1-LKB1- cells we observed a 40–50%
decrease. These results suggest that for cells that do not
express LKB1, the ATP-depleting effects of metformin
are exaggerated when cells are cultured in low glucose
and may lead to increased cell death by necrosis.
Discussion
Previous laboratory models have demonstrated the
anti-proliferative activity of metformin, but have not
comprehensively addressed the role of indirect actions of
the drug on the host as distinct from direct effects on
Figure 6 LKB1 expression is required for metformin induced increase in glucose consumption and lactate production. (a, b) MC38
and LLC1 cells were treated in 2% FBS DMEM with either 2.5 or 15mM glucose, with or without 5mM metformin for 48 h. Data are
expressed as the fold change in glucose consumption when cells were treated with metformin compared with vehicle. For both MC38 and
LLC1 cells, we observed a substantial metformin-induced increase in glucose consumption at both high and low glucose concentrations.
We observed very little change in glucose consumption in MC38-LKB1- and LLC1-LKB1- cells. (c, d) MC38 and LLC1 cells were treated
in 2% FBS DMEMwith either 2.5 or 15mM glucose, with or without 5mM metformin for 48h. We observedB2.5-fold increased lactate
production in both MC38 and LLC1 cells treated with metformin compared with vehicle at both glucose concentrations; however, we
observed only a 1.3 fold increase in lactate production for MC38-LKB1- and LLC1-LKB1- cells.
Figure 7 LKB1 expression inﬂuences cellular ATP levels following metformin exposure. MC38 (a) and LLC1 (b) cells were treated in
2.5 or 15mM glucose for 48 h with or without 5mM metformin. Data are expressed as fold change in cellular ATP concentration in
the presence of metformin compared with vehicle. We observed that metformin decreased ATP levels in MC38 cells at both high and
low glucose concentrations. In MC38-LKB1-, metformin depleted ATP to a greater effect (to 20 and 34% of control conditions in
MC38þF and MC38þG, respectively), while having minimal effect on ATP depletion when these cells were treated at high glucose
concentrations. LLC1 cells also showed greater ATP depletion (to 10% of control) in the absence as compared with the presence of
LKB1 expression, similar to MC38.
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transformed cells. This is an important issue, as the
epidemiologic studies that suggest anti-neoplastic activ-
ity of the drug were conﬁned to patients with type II
diabetes, where metformin lowers insulin levels. It is
unclear if the effects of the drug on cancer end points in
diabetic individuals, which have an increased cancer
burden relative to non-diabetics (Larsson et al., 2005,
2007), are relevant to the general population.
By using an experimental model that allowed us to
treat diet and LKB1 expression by the neoplasm
as variables, we characterized an interaction between
host nutritional status and the anti-neoplastic activity of
metformin. In mice with diet-induced hyperinsulinemia,
insulin receptor activation in neoplastic tissue and
growth of an insulin-responsive tumor were increased
relative to that seen in mice on the control diet, in
keeping with epidemiological evidence for an adverse
effect of type II diabetes on neoplastic disease (Vigneri
et al., 2009). Metformin abolished the excess tumor
growth associated with the high-fat diet and hyperinsu-
linemia, regardless of LKB1 expression by the tumor.
This anti-neoplastic activity was associated with a decline
in circulating insulin levels and with reduced insulin
receptor activation in neoplastic tissue, suggesting simila-
rities to the mechanisms underlying tumor growth
inhibition by dietary restriction (Kalaany and Sabatini,
2009; Pollak, 2009). Dietary restriction involves reduction
of insulin and IGF-I levels from normal to sub-normal
ranges, although metformin reduces insulin levels sig-
niﬁcantly only in the setting of baseline hyperinsulinemia.
This is consistent with our observations that the indirect
actions of metformin involving reduced activation of
insulin receptors in neoplastic tissues were conﬁned to
animals with diet-induced hyperinsulinemia.
In mice without diet-induced hyerinsulinemia, the
anti-neoplastic activity of metformin was not related to
any change in insulin levels, but was instead conﬁned
to LKB1-deﬁcient cancer. Although we and others
have observed direct, LKB1-AMPK-dependent growth
inhibition of cancer cells in vitro (Zakikhani et al., 2006,
2008), we did not observe such an effect in vivo, even
though we documented that the metformin administra-
tion protocol we employed activated the LKB1-AMPK
pathway in neoplastic cells when it was functional.
Rather, LKB1-deﬁcient tumors showed greater growth
inhibition by metformin in vivo, together with in vitro
observations of increased necrosis and reduced ATP
levels in response to metformin exposure combined with
low glucose concentrations.
Previous work (Russell III et al., 2004; Sakamoto
et al., 2005) indicated that loss of function of LKB1 or
AMPK in muscle can adversely affect the energy balance
in that tissue. Our results suggest that there are
conditions in the context of neoplasia where LKB1-
dependent AMPK signaling acts in a manner consistent
with its ancient evolutionary role to favor cell survival
under conditions of energy stress, and that, under certain
conditions, loss of function of the tumor suppressor
LKB1 therefore leads to sensitivity to metformin. The
fact that sensitivity is conferred by loss of a tumor
suppressor predicts a favorable therapeutic index, and
indeed metformin is well tolerated systemically at doses
that inhibit growth in the LKB1-deﬁcient tumor model.
Somatic cell mutations of LKB1 are common in human
lung, cervical and squamous cancers (Sanchez-Cespedes
et al., 2002; Ji et al., 2007; Wingo et al., 2009) and
a variety of LKB1 null neoplasms arise in patients
with Peutz–Jeghers syndrome (van Lier et al., 2010).
Although LKB1 functions upstream of 12 AMPK-related
kinases (Shackelford and Shaw, 2009) and shRNA
against LKB1 may also affect these related kinases, we
attributed our results to impaired activation of AMPK
and downstream targets, as our results are consistent
with those observed in AMPK null mouse embryonic ﬁbro-
blasts under similar experimental conditions as shown in
Buzzai et al. (2007). In addition, we did not observe
differences in tumor volume between MC38 and MC38-
LKB1 tumors in either dietary group, thus implying
that, in our model, knockdown LKB1 does not affect
tumor volume.
Our results justify translational research regarding the
activity of biguanides in these settings, as a situation
where loss of a tumor suppressor confers sensitivity to a
therapeutic strategy represents an attractive therapeutic
opportunity.
There is enthusiasm for investigation of novel
therapies that target tumor cell metabolism (Kroemer
and Pouyssegur, 2008; Tennant et al., 2010), and the
large number of ongoing and planned clinical trials
of biguanides represent important examples of this
research direction. Our results suggest that any clinical
anti-neoplastic activity of this agent will vary according
to the metabolic characteristics of patients and the
molecular pathology of tumors. Therefore, rigorous
evaluation of the clinical activity of biguanides in cancer
patients will require the use of relevant predictive
biomarkers, as well as the selection of a compound
and dose capable of achieving sufﬁcient drug levels in
tumors as well as liver. Recently reported experimental
data (Engelman and Cantley, 2010; Hosono et al., 2010;
Memmott et al., 2010; Pollak, 2010) raise the possibility
that the reduction in tumor burden associated with
metformin use may be attributable to a prevention
effect targeting at-risk epithelial cells rather than a
treatment effect on transformed cells. The mechanisms
we describe, including indirect growth inhibition related
to reduction in insulin levels, direct AMPK dependent
growth inhibition, and cell death associated with
metformin-induced ATP deﬁciency in LKB1 deﬁcient
cells, are likely relevant to both treatment and preven-
tion, and deserve investigation in the context of both




The 60 male C57BL/6 mice were purchased from Charles River
(Saint-Constant, Que´bec, Canada) at 5–6 weeks of age and were
put on either a high fat or a control diet ad libitum for 12 weeks.
Diets were purchased from Harlan Teklad (Madison, WI, USA).
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The high-fat diet consisted of 18.8% protein, 39.8% fat (lard)
and 41.4% carbohydrate, and the diet provided 4.3kcal per
gram consumed. The control diet consisted of 16% protein,
3.5% fat and 60% carbohydrate, and provided 3.3kcal per gram
consumed. All protocols were approved by the McGill
University Animal Care and Handling Committee.
Metformin
Following 12 weeks on the respective diets, 15 mice in each
dietary group were subdivided into groups that were adminis-
tered metformin (Sigma Aldrich, St-Louis, MO, USA).
Mice were given daily i.p. injections of metformin at a dose
of 50mg/kg dissolved in 0.2ml phosphate-buffered saline.
Vehicle-treated mice were given daily i.p. injections of
phosphate-buffered saline of equal volume.
Cells
In vivo and in vitro experiments were done with MC38 colon
carcinoma, a mouse tumor cell line derived from a C57BL/6
mouse (generously donated by Dr Pnina Brodt) and LLC1
purchased from the ATTC (Manassas, VA, USA). Cells were
transfected with either a control shRNA or shRNA against the
expression of LKB1 using two shRNAs. All reagents and
shRNA constructs were purchased from Open Biosystems
(Huntsville, AL, USA). Cells were maintained in DMEM with
4 mg/ml puromycin to maintain the growth of transfected cells.
Insulin ELISA
Insulin ELISA was performed on blood taken from mice
following 12 weeks on the respective diets and again at the time
of sacriﬁce. Insulin ELISA kits were purchased from Millipore
(Billerica, MA, USA).
Immunoblotting
Lysates were made from tissue taken at the time of sacriﬁce.
Antibodies against LKB1, p-p53, p53 total, p-AMPK, AMPK
total, ATG, LC3, p-acetyl CoA carboxylase, ACC Total and
B-Actin were purchased from Cell Signaling Technologies
(Danvers, MA, USA). Antibodies against p-insulin receptor
and insulin receptor total were purchased from Millipore.
Secondary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Bands were quantiﬁed
with Scion Image (Frederick, MD, USA).
Cell death analysis
Cell death was measured using the Annexin V: PE Apoptosis
Detection Kit I (BD Biosciences, San Jose, CA, USA). Brieﬂy,
cells were harvested at 36 (LLC1) or 72 h (MC38), collected,
and resuspended in Annexin V buffer with Annexin V and
7-amino actinomycin for 20min. Cells were resuspended in
phosphate-buffered saline and analyzed by ﬂow cytometry
using a FACS Calibur (Beckton Dickenson, Franklin Lakes,
NJ, USA) equipped with CellQuest software (BD Biosciences).
ATP measurement
Cellular ATP levels were measured using the Invitrogen ATP
Determination Assay (Carlsbad, CA, USA) (Fantin et al.,
2006). Cells were treated in 2% fetal bovine serum DMEM
supplemented with either 2.5 or 15mM glucose, with or
without 5mM metformin, for 48 h. The kit was used as per
the manufacturer’s instructions, with 2 105 cells per well.
Glucose consumption
Supernatants from treated cells were used for glucose consump-
tion as described in Blake and McLean (1989). Results were
indexed to cell-free media and to the number of cells.
Lactate production assay
Lactate production was measured with supernatants collected
from treated cells and results were indexed to the number of
cells. Lactate was quantiﬁed using BioVision Lactate Assay
Kit purchased from BioVision (Mountain View, CA, USA).
Statistical analyses
For tumor data, before statistical analysis, data were
square-root transformed to satisfy the assumptions of analysis.
Statistical signiﬁcance was evaluated using the GLM Proce-
dure. A one-way analysis of variance was used to determine
pairwise comparisons of means and least-squares means
multiple unpairwise comparisons of means (LSMEANS state-
ment with Bonferroni correction) were applied. All statistical
analyses were performed using Statistical Analysis System
software, version 9.1.3 (SAS Institute, Cary, NC, USA), with
the P values o0.05 considered signiﬁcant. P values are given
for analysis of data over the 17-day tumor growth period.
For direct comparison between two groups (such as
comparing dietary effect on insulin levels) the student’s t-test
was used in the Microsoft Excel Program (Seattle, WA, USA).
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